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PRESENTACIÓN 
 
El estrés replicativo (RS) en el DNA está entre las formas más comunes y peligrosas de estrés 
genotóxico, que tiene lugar cuando la progresión de las horquillas de replicación se detiene a 
causa de lesiones endógenas o exógenas. Esto frecuentemente lleva a a la acumulación de DNA 
de cadena simple (ssDNA), el cual es altamente inestable. Si se da de forma persistente, el RS 
promueve roturas de doble cadena en el DNA (DSBs) y reordenamientos genómicos que pueden 
ser tóxicos para la célula. La cinasa ATR es uno de los componentes clave en la respuesta al RS, y 
promueve la activación del punto de control en G2/M del ciclo celular, a la vez que promueve la 
estabilización de las horquillas de replicación atascadas. La inhibición de ATR lleva a una 
acumulación de RS e impide la activación del punto de control G2/M, causando así un colapso 
celular debido a catástrofe mitótica. 
El presente trabajo se ha centrado en la investigación de los mecanismos básicos de la toxicidad 
derivada de RS, y en la identificación y exploración de tumores especialmente sensibles a 
inhibidores de ATR. En la primera parte hemos estudiado el rol de FBH1, una helicasa de DNA 
que parece estar involucrada en el proceso de acumulación de ssDNA durante el RS así como en 
la regulación de la respuesta a los DSBs derivados de RS. Nuestro estudio nos ha llevado a 
concluir que en ratones, FBH1 tiene una contribución limitada en estos procesos y el impacto de 
su deleción es menor, tanto en fondos genéticos silvestres como en fondos con defectos en la 
función de reparación del DNA. La falta de un fenotipo puede ser debida a mecanismos 
compensatorios o factores redundantes presentes en mamíferos. 
En la segunda parte del trabajo hemos explorado el papel del RS en el sarcoma de Ewing. Esta 
neoplasia se caracteriza por una translocación entre EWSR1 y un factor de transcripción, siendo 
FLI1 el más frecuente. La proteína de fusión resultante de la traslocación (EWS/FLI1) actúa 
como factor de transcripción oncogénico, lo cual se ha demostrado ampliamente, y es 
considerado el factor desencadenante de la tumorigénesis. Sin embargo no se ha puesto tanta 
atención en la función de EWS, la proteína producto de EWSR1, y en cómo una pérdida de 
función de EWS puede contribuir a la tumorigénesis en los sarcomas de Ewing. Nuestro trabajo 
demuestra en primer lugar que los sarcomas de Ewing estás sujetos a altos niveles de RS, y por lo 
tanto son candidatos susceptibles de ser tratados con inhibidores de ATR. Seguidamente 
demostramos que la fuente de RS en los sarcomas de Ewing son los bucles-R, y que su 
acumulación  es debida a la pérdida de función de EWS. Especulamos que eso se podría deber a 
un efecto dominante-negativo de EWS/FLI1 sobre EWS. En base a ello proponemos un 
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modelo para la función de EWS en la supresión de bucles-R, por la cual la auto-agregación de 
EWS alrededor de los bucles-R promueve su eliminación. Finalmente describimos un fenotipo 
de neurodegeneración en ratones adultos en los que se ha deplecionado EWS, lo cual apunta a 
una función de EWS en la prevención de neurodegeneración asociada a esclerosis lateral 
amiotrófica. 
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ABSTRACT 
 
DNA replication stress (RS) is one of the most common and dangerous forms of genotoxic 
stress, which occurs when the progression of replication forks is halted by endogenous or 
exogenous lesions. This frequently leads to the accumulation of highly unstable single-stranded 
DNA (ssDNA). If persistent, RS leads to DNA double-strand breaks (DSBs) and genomic 
rearrangements that are cell-toxic. The ATR kinase is one of the key players in the response to 
RS, and triggers the activation of the G2/M checkpoint while it promotes the stability of stalled 
replication forks. ATR inhibiton leads to an accumulation of RS and impairs checkpoint 
activation, thereby causing cells to collapse due to mitotic catastrophe. 
Investigating the basic mechanisms of RS-driven toxicity and exploring tumors that are especially 
sensitive to ATR inhibitors constituted the core of the present work. On the first part we have 
studied the role of FBH1, a DNA helicase thought to mediate the accumulation of ssDNA 
during RS and to regulate the response to RS-derived breakage. Our study leads to conclude that 
in mice, the contribution of FBH1 in such processes has a minor impact either in physiological 
conditions or in a context of defective DNA damage repair. This might be due to compensatory 
mechanisms or redundant factors that evolved in mammals. 
On the second part we explored the role of RS in Ewing sarcomas. These neoplasias bear a 
translocation between EWSR1 and a transcription factor, most frequently FLI1. Evidence exists 
that the resulting fusion proteins (most commonly EWS/FLI1) act as oncogenic transcription 
factors and cause tumorigenesis. Less attention has been put on the actual role of EWS, the 
product of EWSR1, and how a loss of function of EWS can impact on tumorigenesis. Our work 
firstly demonstrates that Ewing sarcomas suffer a high degree of RS and therefore are suitable 
candidates for treatment with ATR inhibitors. Next we demonstrate that R-loops are responsible 
for RS in Ewing sarcomas, and that R-loop accumulation is caused by the absence of EWS 
activity. This might be due to a dominant-negative effect of EWS/FLI1 over EWS. Furthermore, 
we propose a model for EWS R-loop-suppressor function, by which self-aggregation around R-
loops promotes R-loop removal. Finally we describe a phenotype of neurodegeneration in adult 
EWS-depleted mice, which reveals a role for EWS in preventing ALS-linked neurodegeneration. 
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INTRODUCTION 
1. Taking care of the genome 
The genome is the genetic material of an organism. In the vast majority of species, it consists of 
DNA molecules formed by two complementary nucleic acid strands. A copy of the genome is 
packed in the nucleus of every cell, and faithful duplication and transmission to daughter cells 
ensures perpetuation of the species. DNA mutations, deletions, translocations and a variety of 
genomic rearrangements can lead to malfunctioning of the cellular machinery, and this might 
translate into a range of outcomes, from mild disease to lethality (Ciccia and Elledge, 2010). To 
prevent this, organisms have evolved to incorporate several mechanisms to respond to and 
repair DNA damage. 
1.1. Damage sources 
A variety of conditions and insults can potentially damage DNA. UV light, ionizing radiations or 
reactive oxygen species (ROS) are exogenous insults that can generate DNA lesions: pirimidine 
dimers, double-stranded breaks (DSB) and oxidized DNA bases respectively. The endogenous 
metabolism of the cell is also a source of DNA damage: metabolic pathways that generate ROS 
and DNA metabolism constantly results in DNA alterations such as dNTP misincorporation or 
chemical modifications. For example, the rate of depurination for mammalian DNA corresponds 
to the loss of 9.000-10.000 bases per day, and transmethylation reactions of S-
Adenosylmethionine with DNA result in the daily accumulation of 600 cytotoxic 3-
methyladenine residues (Hoeijmakers, 2009; Lindahl and Barnes, 2000). A particularly interesting 
endogenous source of DNA damage is replication stress (RS), associated to the replication of the 
genome in cycling cells. RS generally leads to generation of long threads of single-strand DNA 
(ssDNA), which is toxic for the cell, and to replication fork stalling which, if not stabilized, might 
end up in fork collapse and DSB generation(Lecona and Fernandez-Capetillo, 2014; Lopez-
Contreras and Fernandez-Capetillo, 2010; Zeman and Cimprich, 2014). 
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1.2. The DNA damage response (DDR) 
The cell relies on a network of molecular pathways known as the DNA damage response (DDR) 
to repair DNA alterations and maintain genome integrity (Harper and Elledge, 2007; Jackson and 
Bartek, 2009). The DDR is organized hierarchically and is subjected to a precise spatiotemporal 
regulation. Early in the DDR, a variety of sensors work in detecting DNA lesions. The PIKK 
kinases (including ATM, ATR and DNA-PK) are then recruited to the sites of damage and 
orchestrate signaling cascades that are amplified by transducers, ultimately leading to the 
activation of effector proteins that promote a variety of cellular responses (Figure 1). At least 
two cellular responses are essential: one is the recruitment of repair factors to the DNA lesion in 
order to reestablish genome integrity, and the other is the regulation of cell cycle progression in 
order for the repair events to take place. One early and pivotal target of ATM and ATR is the 
phosphorylation of histone variant H2AX, known as γH2AX (Rogakou et al., 1998). This 
chromatin mark expands for up to 1-2 megabases around the site of damage and forms 
microscopically visible aggregates termed “foci”. Foci serve as repair nodes for recruitment of 
multiple DNA repair factors and are important for amplification of the signaling in order to 
trigger cell cycle checkpoints (Fernandez-Capetillo et al., 2002; Harper and Elledge, 2007; Lukas 
et al., 2011). Additional regulatory mechanisms that mediate factor recruitment to foci include 
ubiquitilation and sumoylation (Chapman et al., 2012; Ciccia and Elledge, 2010). In parallel, the 
signaling is transmitted to Chk2 and Chk1, which subsequently activate cell cycle checkpoints 
and arrest or slow down cell cycle progression in order to give the cell time to repair DNA 
lesions before proceeding to DNA replication or mitosis. In this manner, the PIKKs orchestrate 
the repair of the DNA damage in coordination with cell cycle progression. The amount, nature 
 
 
Figure 1 
Model for the DDR. The DDR has a 
hierarchical organization. The presence of 
a lesion in the DNA is recognized by 
various sensor proteins. These initiate 
signaling pathways that are transduced to 
effector proteins, which in turn mediate a 
variety of cellular processes, including 
DNA repair, cell-cycle arrest, apoptosis or 
senescence, replication fork stability, 
chromatin remodeling, regulation of 
transcription and regulation of RNA 
processing. 
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or persistence of DNA damage can eventually lead to activation of pro-apoptotic or senescence 
pathways. 
1.3. Mechanisms of DNA damage repair 
Some types of simple lesions can be repaired through specific mechanisms that do not generally 
require an arrest of the cell cycle, such as the mismatch repair (MMR) pathway for mispaired 
DNA bases, or the base excision repair (BER) pathway for chemically altered bases (Jiricny, 
2006; Lindahl and Barnes, 2000). However, more complex DNA lesions converge to the 
activation of common DDR pathways. On the one hand, some lesions evolve spontaneously or 
are actively processed into DSBs, which are amongst the most hazardous forms of DNA 
damage. On the other hand, RS can lead to fork stalling; reaching mitosis with under-replicated 
DNA can have catastrophic consequences for cells. Furthermore, stalled forks that are not 
stabilized can collapse and give rise to one-ended DSBs (Figure 2). In the following sections the 
main DDR pathways that respond to DSBs and RS are reviewed. 
 
Figure 2 
Models for ATM and ATR activation. (A) Formation of a DSB leads to the recruitment of the MRN complex and activation of ATM. This 
results in generation of γH2AX and downstream signaling to CHK2 – cell-cycle arrest and to local recruitment of repair factors for DSB 
repair. (B) A ssDNA-dsDNA junction at a stalled fork is coated with RPA, which leads to the recruitment of 9-1-1 and ATR-ATRIP. 
Activation of ATR leads to phosphorylation of downstream CHK1, which in turn activates cell-cycle arrest and promotes stabilization of the 
stalled fork. Adapted from (Cimprich and Cortez, 2008). 
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1.3.1. Double-stranded breaks (DSB) 
DSBs are some of the most deleterious forms of DNA damage: if not properly processed they 
can give rise to chromosomal translocations and complex genomic rearrangements. In fact, 
defective DSB repair is associated with a variety of disorders, including developmental, 
neurological or immunological deficiencies and development of cancer (Jackson and Bartek, 
2009). DSBs can be repaired through at least 4 different pathways: non-homologous end joining 
(NHEJ), alternative NHEJ (alt-NHEJ), homologous recombination (HR) or single-strand 
annealing (SSA) (Ciccia and Elledge, 2010). Following generation of a DSB, poly(ADP-ribose) 
polymerases (PARP), mainly PARP1/2, recognise the break and synthesize PAR chains on 
histones in the vicinity. This is one of the earliest events of the DDR and PAR chains serve as a 
transient platform for recruitment of repair factors (Schreiber et al., 2006). 
The NHEJ pathway drives straight religation of two DNA ends, independently of sequence 
homology (Figure 3). As soon as a DSB arises, the sensor heterodimer Ku70/Ku80 (Ku) 
competes with PARP1/2 for binding of the double-stranded ends, where it keeps them in close 
proximity. Ku recruits and activates the DNA-PK catalytic subunit (DNA-PKcs) (Mahaney et al., 
2009), which mediates limited DNA end processing (Meek et al., 2008). XRCC4/LIG4 is then 
recruited and promotes the religation of the DNA ends (Mahaney et al., 2009). A particular 
physiological process that elicits the NHEJ pathway is the genomic editing in B and T cells 
known as V(D)J recombination, that occurs during lymphocyte maturation. In this process, 
RAG1/2 cleaves DNA at defined sites and generates programmed DSBs. Segments of DNA are 
eliminated and the lasting DNA ends are religated (Market and Papavasiliou, 2003). Similarly, 
class-switch recombination (CSR) in activated B cells invokes NHEJ to edit DNA and generate 
new immunoglobulin isotypes (Stavnezer et al., 2008). 
Alt-NHEJ operates as a backup to NHEJ and is triggered by PARP1/2 (Figure 3). Repair 
through Alt-NHEJ requires a limited end resection (around 5-25 nt) which serves to drive 
microhomology-directed end joining (You and Bailis, 2010; Yun and Hiom, 2009). 
HR drives homology-directed repair of a DSB (Figure 3). PARylation of the break site by 
PARP1/2 facilitates the recruitment of repair factors, including the MRN (MRE11, RAD50 and 
NBS1) complex and ATM. RAD50 directly binds the DNA ends, while MRE11 interacts with 
RAD50 and contains endonuclease and exonuclease activities, important for the initial steps of 
DNA end resection (Williams et al., 2007). NBS1 is proposed to interact with MRE11 and 
facilitate the recruitment and activation of ATM (Kanaar and Wyman, 2008). ATM regulates 
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downstream signaling to cell cycle regulators through CHK2, and promotes DNA end resection, 
which consists on the degradation of the 5’ strand and generation of 3’ protruding ssDNA ends. 
End resection is carried out initially by CtIP in association with BRCA1 (Huen et al., 2010). 
Later, EXO1 and the BLM helicase take over to promote extensive resection (Bolderson et al., 
2010). As ssDNA is generated it is rapidly coated by Replication Protein A (RPA; a 
heterotrimeric complex composed by RPA1, RPA2 and RPA3), which stabilizes ssDNA (Wold, 
1997). RPA-ssDNA molecules recruit the ATR/ATRIP complex through direct interaction with 
ATRIP (Zou and Elledge, 2003). At the site of damage, ATR contributes to regulation of the 
repair process along with ATM. Phosphorylation of RPA by ATM/ATR facilitates replacement 
of RPA by RAD51, a rate-limiting process mediated by BRCA2 (West, 2003). The resulting 
RAD51-ssDNA nucleofilament then undergoes strand invasion and annealing to a homolog 
sequence (in somatic cells, usually the sister chromatid). This gives rise to a D-loop structure 
with two Holliday junctions (HJ; four-way DNA junction) that can be processed in different 
ways. It can undergo synthesis-dependent strand annealing (SDSA) mediated by RTEL (Barber 
et al., 2008), but the most common pathway is the generation of a double Holliday junction 
(dHJ) (West, 2003). dHJ can either be dissolved by the BLM/TOPOIIIa complex or resolved by 
MUS81/EME1, SLX1/SLX4 or GEN1 nucleases. Dissolution leads to the restoration of the 
two chromatids without a chance of crossover, while resolution implies that 50% of the events 
will end up with a crossover, that is, a chromatid exchange at each side of the cleavage point 
(Andersen et al., 2009; Ciccia et al., 2008; Fekairi et al., 2009; Ip et al., 2008; Munoz et al., 2009; 
Svendsen et al., 2009). HR responds not only to spontaneous breaks, but also to programmed 
DSBs in meiotic cells occurring at the first meiotic division, which serves to generate allelic 
combinations distinct from the ones at the parental germ line (Keeney and Neale, 2006). 
In SSA, a DSB that occurs within or near a repetitive sequence is repaired through removal of a 
fragment of DNA and pseudo-homologous annealing between repeats (Figure 3). This process 
requires end resection, analogously to HR, but RAD52 works instead of RAD51 in forming the 
nucleoprotein filament at resected DNA ends. ERCC1 and XPF then mediate SSA (Hartlerode 
and Scully, 2009). 
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Figure 3 
DNA repair pathways involved in the repair of DSB. A) Rapid association of Ku to DSBs promotes NHEJ by recruiting DNA-PKcs. 
Sequential autophosphorylation events on DNA-PKcs favor limited processing of DNA ends and DNA ligation. B) MRN complex, recruited 
to DSBs by PARP in competition with Ku, mediates initial DSB resection together with CtIP and BRCA1 to promote HR in S and G2. 
Extensive DSB resection and formation of RPA-coated ssDNA ends is induced by EXO1 and BLM. ATM plays a central role in the 
regulation of DSB resection. Displacement of RPA from the ssDNA ends and assembly of RAD51 nucleofilaments mediated by BRCA2 
leads to strand invasion into homologous DNA sequences. Recruitment of RAD51 to ssDNA ends is regulated by the ATR pathway, which 
is activated following DSB resection. HJ structures formed after strand invasion can be cleaved by MUS81/EME1 or displaced by RTEL1 
during SDSA to generate crossover or non-crossover events, respectively. Branch migration of the HJs results in the generation of a dHJ. 
Dissolution of dHJs by the BLM/TOPOIII generates noncrossovers, whereas dHJ resolution by the nucleases GEN1 and SLX1/SLX4, in 
association with MUS81/EME1, can generate both crossover and noncrossover events. C) limited DSB resection in G1 results in alt-
NHEJ. D)Following DSB resection, ssDNA ends with homologous sequences can be directly annealed by RAD52. Figure adapted from 
(Ciccia and Elledge, 2010). 
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Pathway choice in DSB repair  
NHEJ is an error-prone DSB repair mechanism as the direct ligation of two DNA ends 
frequently results in small nucleotide deletions, insertions or substitutions, or translocations if the 
two joined ends correspond to different loci within the genome. Conversely, HR is considered to 
be error-free because it uses a template strand (most frequently the sister chromatid) to 
accurately repair the break and restore sequence integrity. The repair pathway choice when a 
DSB occurs is conditioned by several determinants. In cycling cells, HR is highly favoured 
during S and G2 phases, where a sister chromatid is available. Actually, it is restricted to these 
phases, since unscheduled HR occurring in G1 can lead to HR-DSB repair based on pseudo-
homologous sequences, which could translate into chromosomal translocations and loss of 
heterozigosity (LOH) events (Agarwal et al., 2006; Llorente et al., 2008). Instead, NHEJ is active 
throughout the cell cycle and is invoked during G1. 53BP1 and BRCA1 are two pivotal 
regulators of DSB repair pathway choice. 53BP1 promotes NHEJ by binding to DSB early in the 
DDR and inhibiting DSB resection (Chapman et al., 2012), and is active throughout the cell 
cycle, as assessed by its recruitment to IR-induced foci at any time. To counteract 53BP1 
inhibitory effect on DSB resection and promote HR, BRCA1 antagonizes 53BP1 during S and 
G2 phases. BRCA1 deficiency is associated with genome instability and defective HR (Moynahan 
et al., 1999), and additional 53BP1 loss alleviates these effects by partially restoring HR 
(Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 2009). 
1.3.2. Replication stress (RS) 
DNA replication must be fulfilled accurately and on time in order to reach mitosis with a fully 
duplicated genome and ensure faithful transmission of genetic information to the daughter cells. 
Slowing, stalling or eventual collapse of replication forks that impede faithful DNA replication is 
commonly referred to as replication stress (RS). Diverse exogenous and endogenous insults 
leading to unrepaired DNA damage, inter-strand crosslinks or dNTP pool depletion are sources 
of RS. Fork stalling poses one of the major threats to genome integrity, since entry into mitosis 
with under-replicated DNA can lead to genomic rearrangements, aneuploidy or mitotic 
catastrophe (Zeman and Cimprich, 2014). Moreover, single-stranded DNA (ssDNA) arises – 
frequently, but not always – during RS and is higly recombinogenic, potentially resulting into 
deleterious genomic rearrangements. ssDNA arises either due to uncoupling of the MCM 
helicase that continues to unwind DNA ahead of the stalled DNA polymerase (Byun et al., 
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2005), due to ssDNA gaps left behind the polymerase, or through other unclear ssDNA-
generating mechanisms.  
Sources of RS 
Replication per se poses a threat to genome integrity, as DNA molecules are subjected to intense 
manipulation; therefore it is an inherent source of RS. Cell types with high proliferative rates are 
more sensitive to RS, and some oncogenes increase the amount of RS by inducing premature 
entry into S-phase or by deregulating replication. In fact, expression of some oncogenes, 
including HRAS, MYC or cyclin E has been described as an important source of RS (Halazonetis 
et al., 2008; Jones et al., 2013; Srinivasan et al., 2013). Their possible mechanisms of action are an 
increase in replication initiation or in origin firing, which can lead to increased probability of 
collisions with transcriptional machinery or to dNTP pool depletion (Bester et al., 2011). dNTPs 
are the fuel for replication and their amount might be limiting, in which case fork progression is 
challenged. Depletion of dNTPs and subsequent RS can be originated due to impaired dNTP 
synthesis or excessive replication origin firing (Beck et al., 2012). 
 ssDNA Nicks and gaps are both sources and consequences of RS. They can arise as a result of 
DNA manipulation, for example during DNA repair or upon abortive topoisomerase I (TopoI) 
activity. As a source of RS, ssDNA nicks and gaps might result in passive generation of a one-
ended DSB when replication forks encounter these lesions. As a consequence of RS, ssDNA 
nicks and gaps can arise if a stalled replication fork bypasses an unrepaired DNA lesion through 
DNA damage tolerance (DDT) pathways (Zeman and Cimprich, 2014). 
Unrepaired DNA lesions, such as inter-strand crosslinks, thymidin dimers or DNA-protein 
crosslinks, become physical barriers to replication fork progression. These can be bypassed by 
the DDT pathways (Mailand et al., 2013). The agents that generate such DNA lesions include 
by-products of cellular metabolism, reactive aldehydes, UV light and chemical mutagens (Brooks 
and Theruvathu, 2005; Ciccia and Elledge, 2010). Misincorporation of rNTPs (ribonucleotides) 
also requires activation of the DDT pathways (Dalgaard, 2012; Nick McElhinny et al., 2010). 
DNA sequences that are intrinsically difficult to replicate are a source of RS. These include 
trinucleotide repeats that can acquire secondary structures (Kim and Mirkin, 2013) and GC-rich 
areas that form G-quadruplexes (Bochman et al., 2012). The RS response reverses the formation 
of such secondary structures through activation of helicases that unwind them.  
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Because both replication and transcription use DNA molecules as a substrate, conflicts might 
arise between the two processes. Collisions between replication forks and transcriptional 
complexes travelling towards each other were shown to be a source of genomic instability 
(Bermejo et al., 2012). The recently described early-replicating fragile sites (ERFS) are genomic 
regions with a high transcription rate that are replicated early in S-phase. ERFS are especially 
prone to breakage, possibly owing to collisions between replication forks and transcriptional 
complexes (Barlow et al., 2013). Topoisomerases work to relieve topological stress generated in 
these scenarios (Tuduri et al., 2009), and deficient Topoisomerase activity leads to RS. Loss of 
RNA processing factors can also derive into RS. For example, slowing of the transcription rate 
or failure to release the transcriptional machinery from the DNA upon termination can promote 
collisions.  
A particular source of RS associated to transcription-replication collisions is R-loop 
accumulation. Newly synthesized RNA can rehybridize to its template DNA to form a 
RNA:DNA hybrid and a displaced ssDNA strand, a structure termed R-loop (Aguilera and 
Garcia-Muse, 2012). While RNA:DNA hybrids have important functions in diverse physiological 
processes, from replication initiation in mitochondrial RNA to immunoglobulin class-switching 
(Chaudhuri and Alt, 2004; Pohjoismaki et al., 2010; Xu and Clayton, 1996), aberrant 
accumulation due to defective mRNA processing can be toxic. RNA:DNA helicases exist that 
unwind R-loops, such as SETX and PIF1 (Alzu et al., 2012; Boule and Zakian, 2007; Kim et al., 
1999), while RNase H1 works to digest its RNA component (Huertas and Aguilera, 2003). 
Deficiencies in these and other factors for RNA metabolism can result in persistent R-loops, 
which are obstacles to replication fork progression and therefore sources of RS. In this regard, 
the lab of Andrés Aguilera made a valuable contribution in the field. The THO complex is a 
central player in RNA metabolism that couples transcription and RNA export. Aguilera and 
colleagues showed that yeast mutants of the THO complex accumulated R-loops and genomic 
instability, and this was due to impaired transcription elongation that lead to transcription-
associated recombination. Together, they postulated R-loops as transcription-dependent 
structures with an impact on genomic integrity (Aguilera and Garcia-Muse, 2012; Huertas and 
Aguilera, 2003). 
The RS response (RSR) 
As part of the DDR, a series of pathways known as the RS response (RSR) are activated upon 
sensing RS in order to limit it and prevent further accumulation (Cimprich and Cortez, 2008; 
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Lopez-Contreras and Fernandez-Capetillo, 2010). During replication, newly generated, exposed 
ssDNA is rapidly coated by RPA. Upon fork stalling, ssDNA-RPA rapidly accumulates. The 
boundary of double-stranded DNA (dsDNA) with a 5’ end adjacent to ssDNA-RPA generates a 
signaling platform for activation of the RSR and recruitment of repair factors (Byun et al., 2005). 
ATR/ATRIP is recruited through direct interaction of ATRIP with the RPA-ssDNA complex. 
RPA-ssDNA also stimulates the loading of 9-1-1 (RAD9-HUS1-RAD1) complex, which brings 
ATR-activating protein TOPBP1 close to the stalled fork. It is the proximity of TOPBP1 to 
ATR what stimulates ATR kinase activity. Downstream of this, ATR phosphorylates chromatin 
(generating the signaling mark γH2AX) and acts locally to perform three functions: stabilize the 
stalled fork, promote the restart of replication and initiate a signaling cascade transduced by 
CHK1. In turn, CHK1 collaborates in stabilizing the fork and triggers global responses including 
the activation of cell cycle checkpoints and the suppression of late origin firing, which gives the 
cell time to fulfill DNA replication (Figure 4) (Cimprich and Cortez, 2008; Lopez-Contreras and 
Fernandez-Capetillo, 2010).  
 
 
Figure 4 
The ATR-mediated RSR. Parental DNA is unwound by the 
MCM complex and replicated by the DNA polymerases. When 
replication stalls at a DNA lesion (red star), DNA synthesis can 
resume downstream, generating a primer-template junction 
that is recognized by ATR-ATRIP. ATR activates CHK1, which 
promotes fork stabilization and restart while impairing cell cycle 
progression. Adapted from (Zeman and Cimprich, 2014). 
 
Importantly, there exist obstacles that promote fork stalling without generation of ssDNA (i.e., 
without helicase-polymerase uncoupling). This is the case for protein-DNA complexes, ICLs, R-
loops or other physical roadblocks ahead of the replication fork that impede fork progression 
(Lambert and Carr, 2013; Zeman and Cimprich, 2014). Under these circumstances, ATR might 
be activated by alternative, RPA-ssDNA-independent mechanisms yet to be understood (Zeman 
and Cimprich, 2014). 
Mechanisms of replication restart  
Once the source of stress is removed (for example, upon restoring of the dNTP pool) stalled 
replication forks can resume replication through at least three ATR-dependent mechanisms. 
First, a stalled fork might undergo remodeling, which enables straightforward restart. Second, the 
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fork might undergo regression by rewinding the parental DNA and extruding the newly 
synthesized strands, giving rise to a so-called “chicken-foot” structure, which resembles a HJ. HJ 
is then a substrate for nucleases and factors that mediate HR in a process in which the newly 
synthesized daughter strand is used as a template to proceed with replication. Third, the HJ is 
processed into a DSB and replication is resumed through break-induced replication (BIR). These 
cleavage mechanisms, although not ideal, would avoid permanent stalling of a replication fork 
(Petermann and Helleday, 2010). Of note, although BIR has been well established in yeast, there 
is weak evidence of conservation in higher eukaryotes (Ciccia and Elledge, 2010). On the other 
hand, the physiological role of the regressed forks or “chicken-foot” structures is under intense 
debate. Whereas they form and are subjected to nuclease cleavage more frequently in the absence 
of appropriate ATR signaling (Cotta-Ramusino et al., 2005; Couch et al., 2013; Hu et al., 2012; 
Sogo et al., 2002), evidence suggests that regression may actually protect the fork from being 
processed into a DSB (Betous et al., 2012). Thus, it is unclear whether fork regression is 
protective, pathological or both. 
Besides the mechanisms of replication fork restart, the cellular machinery also has means to 
resume replication when the source of stress cannot be removed – for example, when facing 
unrepaired DNA lesions. One is the firing of dormant origins. Interestingly, an important 
number of the replication origins that are licensed before S-phase entry, are never actually fired 
in unperturbed conditions. These dormant origins might exist as a backup to resume replication 
in the case of global replication rate slowing due to fork stalling at DNA lesions (Ge et al., 2007; 
Ibarra et al., 2008). A second mechanism is the repriming of the template strand downstream of 
the DNA lesion to enable fork progression, which leaves a ssDNA gap behind (Elvers et al., 
2011; Lopes et al., 2006). The gaps might be filled by template switch and usage of the newly 
synthesized complementary strand as a template, or by specialized translesion synthesis 
polymerases that act in the DNA damage tolerance (DDT) pathway. Translesion synthesis can 
occur after the fork has passed the DNA lesion, or in real-time, as the fork encounters the lesion 
(Zeman and Cimprich, 2014). 
Consequences of RS 
When mechanisms for fork stabilization and replication restart fail, a number of consequences of 
RS arise that have an impact on genome integrity. Common fragile sites (CFS) are late-replicating 
genomic regions especially prone to RS-induced DSB (Debatisse et al., 2012). Its biological 
significance is not well understood and the origin of their fragility is unclear. Several studies point 
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to a sequence-independent fragility. Instead, CFS appear to be devoid of replication origins, 
which would explain an inability to rescue replication through alternative origin firing (Debatisse 
et al., 2012; Le Tallec et al., 2013).  
RS-derived breakage is also frequent at ERFS, regions that undergo replication early in S-phase. 
Because they host a high transcriptional rate, their fragility is probably due to collisions between 
replication and transcription (Barlow et al., 2013). 
Copy-number variants (CNV) are another common outcome of unresolved RS. Stalled fork 
breakage and subsequent error-prone repair appear to be important mechanisms in the 
formation of CNVs with implications for developmental disorders and cancer (Arlt et al., 2009). 
Inducing RS 
A variety of RS-inducing chemical compounds and biological tools have been used in 
experimental settings to study the RSR. Hydroyurea (HU) blocks dNTP syhthesis by inhibiting 
the ribonucleotide reductase (RNR) which leads to dNTP pool depletion (Gagou et al., 2010), 
whereas ATR or CHK1 inhibitors suppress the RSR leading to fork stalling and collapse (Murga 
et al., 2011; Toledo et al., 2011). Camptothecin (CPT) inhibits Topoisomease I (TopoI), an 
enzyme that relieves torsional stress during transcription, and inhibition of TopoI leads to RS 
due to collision of replication forks with stalled transcriptional complexes (Tuduri et al., 2009). 
The so-called antimetabolites impede cell growth by interfering with essential processes required 
for replication. For example methotrexate and fluorouracil compete with intermediate 
metabolites to block de novo synthesis of thymidine and halt DNA replication, and are used as 
chemotherapeutics. In addition, many of the drugs initially used as chemotherapeutic agents, 
including doxorubicin, cisplatin or etoposide, do indeed block replication, and improved 
derivatives with reduced cytotoxicity are still in use in the clinics. 
1.3.3. RS in cancer 
RS is frequently related to cancer (Lecona and Fernandez-Capetillo, 2014). Certain oncogenes 
challenge DNA replication by altering the normal usage of replication origins (Bartkova et al., 
2006; Di Micco et al., 2006; Ekholm-Reed et al., 2004), or by promoting collisions with 
transcription (Jones et al., 2013). These events generate high levels of RS (Halazonetis et al., 
2008; Jones et al., 2013; Srinivasan et al., 2013), which has been shown to lead to genomic 
instability (Barlow et al., 2013; Burrell et al., 2013; Costantino et al., 2014; Dereli-Oz et al., 2011).  
  INTRODUCTION 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
29 
Chromosomal rearrangements, copy number alterations and other reorganizations can result into 
aberrancies such as translocations or LOH, which might contribute to malignant transformation. 
Finally, malignant transformation is frequently accompained by deficient cell cycle checkpoints 
and unrestrained growth. This contributes to further increase RS, thereby closing a positive 
feedback loop that fuels cancer (Figure 5). Similarly, mutations affecting DNA repair 
mechanisms predispose to tumorigenesis as deficient DNA repair can also lead to an 
accumulation of RS when forks encounter DNA lesions. For example, proteins of the Fanconi 
Anemia pathway promote repair of ICLs that block replication fork progress, and mutations in 
these proteins predispose to cancer (Clauson et al., 2013). The RECQ family of DNA helicases 
recognize and process specific toxic structures generated during replication, and mutations in 
these proteins result in syndromes that predispose carriers to tumorigenesis (Croteau et al., 
2014).  
Nonetheless, RS is a double-edged sword. Excessive amounts of RS do not predispose to cancer, 
but rather lead cells to collapse and death (Figure 6) (Murga et al., 2009; Schoppy et al., 2012). 
Such amounts of RS can be induced upon deletion or inhibition of ATR or CHK1, the primary 
response factors to RS. This has important clinical implications that are commented below. 
 
 
 
Figure 5 
RS fuels cancer. Moderate amounts of RS favor 
genomic instability, which can lead to detrimental 
rearrangements such as LOH or gene 
translocations. These events are drivers of 
malignant transformation, which frequently 
promotes unrestrained cell-cycle progression and 
growth, leading to a further increase in RS. This 
positive feedback loop fuels cancer progression. 
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Figure 6 
RS is a double-edged sword. A proficient 
RSR keeps RS levels low and prevents 
genomic instability in proliferating cells. 
Moderate RS levels, either due to 
exogenous sources of RS or to a partially 
deficient RSR, favor malignant 
transformation and tumorigenesis. A fully 
deficient RSR results in excessive RS 
levels that are incompatible with any kind 
of proliferation, and lead cells to collapse 
and death. This principle can be exploited 
as a strategy to selectively kill cancer 
cells (Murga et al., 2009; Schoppy et al., 
2012). 
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2. FBH1: a molecule that promotes RS 
ssDNA accumulates during RS and is toxic for the cell due to its highly recombinogenic nature, 
which might result in genomic instability (Lecona and Fernandez-Capetillo, 2014). One open 
question in the study of the molecular bases of RS is the identification of factors that mediate the 
accumulation of ssDNA. The depletion of such hypothetical factor should theoretically protect 
cells against RS-inducing agents, and would be of high relevance for clinical applications.  
FBH1 is a member of the UvrD family of DNA helicases, first identified in S. pombe. It is 
conserved in fission yeast and higher eukaryotes, but not in budding yeast. FBH1 was initially 
identified as being stimulated by RPA, and 3’-5’ directionality was determined (Park et al., 1997). 
It is a bifunctional protein containing a C-terminal domain with ATP-dependent DNA helicase 
activity and an N-terminal F-Box domain (Kim et al., 2002) (Figure 7A). F-box proteins act as 
substrate recognition factors whithin SCF complexes, which target proteins for ubiquitilation and 
degradation (Patton et al., 1998). The F-box of FBH1 contains an E3 ligase domain which 
provides ubiquitin ligase activity to its SCF complex (SKP1-CUL1-FBH1) (Kim et al., 2004). The 
roles of FBH1 have been a subject of controversy since its identification (Figure 7B). 
 
Figure 7 
Structure and functions of FBH1. (A) FBH1 contains an N-terminal F-box domain with E3 ligase activity and a C-terminal DNA helicase 
domain with affinity for ssDNA and helicase-translocase activity. (B) Diverse functions have been described or proposed for FBH1: pro-
recombinase, anti-recombinase, activation of pro-apoptotic signaling, survival to decatenation stress, and signaling of the intra-S and G2 
checkpoints.  
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In regards to the identification of factors that mediate the accumulation of ssDNA, FBH1 
emerged recently as a putative candidate. Fugger and colleagues showed that cells depleted from 
FBH1 failed to accumulate ssDNA upon exposure to HU, suggesting that FBH1 had an active 
role in promoting ssDNA accumulation. Based on the high recombinogenicity of ssDNA, they 
proposed a pro-recombinase role for FBH1 (Fugger et al., 2009). 
Nonetheless, FBH1 had been previously described as a putative ortholog of Srs2, a canonical 
yeast anti-recombinase (Chiolo et al., 2007).  In fact, hyperrecombinant phenotypes were 
observed in FBH1-deficient strains of S. pombe (Morishita et al., 2005; Osman et al., 2005), 
chicken (Kohzaki et al., 2007) and human cells (Fugger et al., 2009), which might be an outcome 
of unrestrained HR. Several studies support a role for FBH1 in HR, as it is recruited to RS- or 
damage-induced foci (Fugger et al., 2009) where it colocalizes with RAD51 (Osman et al., 2005). 
Furthermore, FBH1 directly interacts with Rad51 in vitro and disrupts the Rad51 nucleofilament 
by means of its ssDNA helicase-translocase activity, while it probably prevents Rad51 re-loading 
onto ssDNA by ubiquitylating it (Chu et al., 2015; Simandlova et al., 2013), consistent with an 
anti-recombinase role. Furthermore, codepletion of both FBH1 and Srs2 in fission yeast leads to 
a growth defect and hypersensitivity to RS-inducing agents, whereas codepletion of FBH1 and 
rqh1 (BLM homolog in fission yeast) is synthetic lethal (Osman et al., 2005; Roseaulin et al., 
2008). Interestingly, these phenotypes are circumvented by inactivation of rad51 or rad51-related 
factors that initiate HR (Osman et al., 2005). A lot of interest in the field was raised around the 
identification of a bona-fide mammalian ortholog of Srs2 anti-recombinase; in this race, another 
candidate was RTEL1 (Barber et al., 2008). This helicase was described as a functional analog of 
Srs2 and was found to be required for genome stability and tumor avoidance. RTEL1 deletion in 
C. elegans lead to characteristic phenotypes shared with yeast Srs2 mutants, and HR was also 
limited by RTEL1 in vitro. 
More recent works suggest that in mammals FBH1 has a minor role in regulating RS-derived 
HR. Instead, its main role would be to promote apoptosis in cells accumulating excessive RS. 
Breaks arising upon fork collapse can be subjected to HR-mediated repair, but this involves a 
risk of aberrant recombination and subsequent chromosomal rearrangements. In cells suffering 
from RS, FBH1 might counteract aberrant recombination at stalled forks by redirecting the 
cellular signaling network towards apoptosis. Mechanistically, FBH1 would promote nuclease-
mediated DSB formation at stalled forks, which would serve as a molecular signal to trigger 
apoptosis (Fugger et al., 2013; Jeong et al., 2013b). This would represent a means for preventing 
perpetuation of aberrant genomic rearrangements and eventually tumoral transformation. 
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Supporting this idea, deleterious mutations at the FBH1 gene have been found enriched in 
melanoma cell lines (Jeong et al., 2013a). Other studies have proposed additional roles for FBH1 
in mitotic and meiotic chromosome seggregation (Laulier et al., 2010; Sun et al., 2011). Mitotic 
progression after decatenation stress by topoisomeraseII inhibition was largely abrogated in 
FBH1-deficient cells, and meiotic seggregation was deficient in fbh1 mutant yeast, correlating 
with increased recuritment of rad51 to break sites. 
Alltogether, we aimed at exploring two main questions. First, whether FBH1 indeed promotes 
RS. If this were the case, deletion of FBH1 should be beneficial in a mouse model suffering from 
RS, such as the ATR-Seckel mouse previously developed in our lab (Murga et al., 2009). Second, 
we wanted to find whether FBH1 is an anti-recombinase. As such, deletion of FBH1 might 
rescue the phenotypes of a BRCA1 mutant mouse, a model with impaired recombination (Xu et 
al., 1999). 
  
  INTRODUCTION 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
34 
3. Targeting RS in Ewing sarcoma 
Deficiencies in the repair of RS-inducing DNA damage can lead to a moderate accumulation of 
RS and favor tumorigenesis, as commented above (Figure 5). By contrast, inhibition of the 
primary response to RS - that is, ATR and Chk1 - leads to a massive accumulation of RS and 
does not favor tumorigenesis, but rather drives cells to death (Murga et al., 2009; Schoppy et al., 
2012). ATR or CHK1 deletion/inhibition is incompatible with any form of cell proliferation; 
also – and especially – with tumoral proliferation. In fact, tumoral cells growing with RS are 
highly dependent on a proficient RSR (Figure 6). On this basis, targeting the RSR through ATR 
and Chk1 inhibition has proved to be a successful strategy for impairing tumoral growth in 
murine models of Eµ-myc lymphoma, H-Ras fibrosarcoma and MLL-ENL AML (Murga et al., 
2011; Schoppy et al., 2012). 
The success of targeting the RSR in cancers with high RS encouraged us to seek for other cancer 
types that might be susceptible to this strategy. In this regard, Ewing sarcomas display a high 
degree of genomic instability and rearrangements (Ferreira et al., 2008; Ohali et al., 2004) but, as 
pediatric cancers, very low frequency of single nucleotide polymorphisms (SNPs) and point 
mutations (Alexandrov et al., 2013), which are caused by a variety of mutagens and are a 
hallmark of other cancer types. These two conditions together are reminiscent of high RS. 
3.1. Ewing sarcoma: molecular pathogenesis 
Ewing sarcoma is the second most common bone tumor affecting children and adolescents 
(Ordonez et al., 2009). While current chemotherapy enables 75% survival for patients diagnosed 
with primary ES, metastasis still correlates with a bad prognosis. ES is a poorly differentiated 
tumor type of bone and soft tissues. It is a member of the Ewing sarcoma Family of Tumours 
(ESFT), which invariably present a reciprocal translocation involving a gene of the FET family 
of DNA and RNA-binding proteins (FUS/TLS, EWS and TAF15) and a transcription factor of 
the ETS family. All translocations involve the substitution of the C-terminal RNA/DNA binding 
domains of the FETprotein with a DNA binding domain contributed by the ETS transcription 
factor (Balamuth and Womer, 2010; Lessnick and Ladanyi, 2012; Ordonez et al., 2009; 
Paronetto, 2013). The most common translocation, accounting for 90% of the cases, is the 
t(11;22)(q24:q12) between the EWSR1 gene and the FLI1 gene, which generates the fusion 
protein EWS/FLI1 (Figure 8). Notably, FET/ETS translocations have also been found in other 
cancers, including malignant melanoma of soft parts (Zucman et al., 1993), extraskeletal myxoid  
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chondrosarcoma (Labelle et al., 1995), myxoid liposarcoma (Panagopoulos et al., 1996) or 
desmoplastic small cell round tumours (Ladanyi and Gerald, 1994).  
EWS/FLI1 chimeric protein has been a subject of intense study as the presumed initiating event 
in Ewing sarcoma (Kauer et al., 2009; Riggi et al., 2008). It behaves as an aberrant transcriptional 
regulator, and its expression in NIH-3T3 cells promotes transformation, revealing it as a bona-
fide oncogene (May et al., 1993a; May et al., 1993b). Indeed, numerous EWS/FLI1-regulated 
genes have been identified (Bailly et al., 1994; Braun et al., 1995; Dauphinot et al., 2001; Fukuma 
et al., 2003; May et al., 1997; Nakatani et al., 2003; Thompson et al., 1996; Wai et al., 2002). 
Mouse models expressing EWS/FLI1 have been generated for the study of Ewing sarcoma and 
development of novel therapies (Lin et al., 2008). However, less attention has been put on the 
loss of EWS function upon translocation, and the actual contribution of EWS in preventing 
tumorigenesis remains largely unexplored. 
3.2. EWS protein: structure and function 
EWS is encoded by the EWSR1 (Ewing Sarcoma breakpoint Region 1) gene, originally identified 
and termed after its translocation in Ewing sarcomas. All three members of the FET family of 
DNA and RNA-binding proteins (EWS, FUS and TAF15) share a very similar structure (Figure 
9A). A SYGQ-rich N-terminal domain is followed by a C-terminal region with nucleic acid 
binding domains containing an RNA recognition motif (RRM), a zinc finger (ZF) and three 
arginine-glycine-glycine (RGG)-rich domains (Paronetto, 2013). Interestingly, EWS has been 
shown to bind diverse nucleic acid substrates, including DNA and RNA G-quadruplexes (via its 
RGG motifs) and ssDNA (Paronetto et al., 2011; Takahama et al., 2011). The three FET 
proteins are cointeractors (Pahlich et al., 2009; Spahn et al., 2003) and generally localize to the 
nucleus (Andersson et al., 2008). 
EWS has been associated to a variety of cellular functions related to RNA metabolism (Figure 
9B). A role in transcription was described based on its interaction with RNA polymerase II 
(RNAPII) (Bertolotti et al., 1996; Bertolotti et al., 1998), its association with TFIID (Bertolotti et 
 
 
 
Figure 8 
EWS/FLI1 translocation in Ewing sarcoma. The fusion protein 
resulting from the initiating translocation in Ewing sarcoma is 
composed of an N-terminal SYGQ-rich domain contributed by 
EWS and a C-terminal DNA-binding domain contributed by FLI1 or 
ETS family transcription factor. 
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al., 1998), and with several transcriptional activators and repressors including OCT4, Brn3a, CBP 
and p300 (Araya et al., 2003; Fujimura et al., 2001; Gascoyne et al., 2004; Lee et al., 2005; 
Thomas and Latchman, 2002). It was also involved in RNA splicing; interaction of EWS with 
components of the spliceosome and splicing factors were described (Michaud and Reed, 1993; 
Yang et al., 2000), and a role for EWS in DNA damage-induced alternative splicing was 
proposed (Paronetto et al., 2014; Paronetto et al., 2011). Genome surveillance functions have 
also been associated to EWS (Figure 9B): it interacts with BARD1 which, together with BRCA1, 
promotes repair of DNA damage (Spahn et al., 2002), and it is required for resistance to CPT, an 
RS-inducing agent (O'Connell et al., 2010). Interestingly, all three FET proteins are recruited to 
laser microirradiation stripes in a PARP-dependent manner (Britton et al., 2014; Mastrocola et 
al., 2013; Rulten et al., 2014). While the contribution of these activities to physiological functions  
 
Figure 9 
Structure and functions of EWS and related FET proteins. (A) EWS contains an N-terminus with SYGQ repeats and a C-terminus with 
nucleic acid binding domains containing an RNA recognition motif (RRM), a zinc finger (ZF) and three arginine-glycine-glycine (RGG)-rich 
domains. The structure is highly conserved across the FET family of DNA and RNA binding proteins formed by EWS, FUS and TAF15. (B) 
Several functions have been described for EWS in transcription, mRNA processing, RNA transport and genome surveillance (DNA 
damage response and RSR). EWS has been linked to cancer and neurodegeneration. 
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is not well understood, absence of EWS protein leads to a number of phenotypical traits at the 
organism level. A knockout mouse with constitutive deletion of EWS showed a high perinatal 
mortality, XY chromosome asynapsis at meiosis, defective B-cell development, hypersensitivity 
to ionizing radiation and an altered dynamics in hematopoietic stem cell population, all 
consistent with a role for EWS in preventing genomic alterations (Li et al., 2007). Similarly, a 
FUS-KO mouse showed embryonic lethality and genomic instability (Hicks et al., 2000). 
3.3. EWS protein in disease 
EWS protein has been linked to cancer mainly based on the known translocations leading to 
Ewing sarcoma. Nonetheless, its roles in genome surveillance suggest a putative function as a 
tumor suppressor, which has not been proven. 
Defects in RNA metabolism have been linked to disease in the nervous system. Cytoplasmic 
aggregates of RNA binding proteins are frequent clinical hallmarks of neurodegenerative disease. 
In this regard, all three FET proteins are recruited in cytoplasmic aggregates in frontotemporal 
dementia (FTD) (Bosco et al., 2010; Huey et al., 2012; Kwiatkowski et al., 2009; Mackenzie and 
Neumann, 2012; Neumann et al., 2011; Takanashi and Yamaguchi, 2014). Furthermore, 
mutations in FUS are causative of familial cases of amyotrophic lateral sclerosis (ALS) (Bosco et 
al., 2010; Kwiatkowski et al., 2009). These findings suggest a neuroprotective role common for 
FET proteins. 
In this project we aimed at assessing the suitability of Ewing sarcomas for treatment with ATR 
inhibitors and at unraveling the underlying causes of RS in this tumor type. At the molecular 
level we wanted to further understand the role of EWS and the impact of its deficiency in cancer 
and neurodegenerative disease. 
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OBJECTIVES 
 
PART I 
1. To evaluate the in vivo contribution of FBH1 to the maintenance of genome integrity 
 - To understand the molecular mechanisms of FBH1 contribution to RS and HR 
 - To assess the impact of FBH1 deletion in mouse models of high RS and defective HR 
 
PART II 
2. To assess the suitability of Ewing sarcomas to treatment with ATR inhibitors 
 
3. To understand the underlying causes of RS in Ewing sarcomas 
 - To dissect the molecular contributions of wild type EWS and EWS/FLI1 in RS 
 
4. To explore the impact of EWS deficiency in disease 
 - To understand the molecular role of EWS protein 
 - To assess the tumorigenic potential of R-loop-driven RS. 
 - To assess the contribution of EWS deletion in neurodegeneration. 
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MATERIALS AND METHODS 
 
1. Mouse biology 
1.1. Mouse models 
Targeting constructs for the generation of the Fbh1 and Ewsr1 gene trapped alleles were obtained 
from the European Conditional Mouse Mutagenesis Program (EUCOMM) at the International 
Knockout Mouse Consortium (IKMC). Linearized vectors were electroporated into R1 
(129X1/SvJ x 129S1) mouse embryonic stem cells. Neomycin-resistant colonies were screened 
by southern blotting for identification of recombinant clones, and selected clones were 
aggregated for generation of chimeras. ATRSeckel (Murga et al., 2009) and Brca1Δ11 (Xu et al., 1999) 
mice have been described. Mouse colonies were maintained under Specific Pathogen Free 
conditions with constant temperature and humidity, according to the institutional Spanish 
National Cancer Research Centre (CNIO) guidelines, in a mixed C57BL/6-129/Sv background. 
All mouse work was performed in accordance with the Guidelines for Humane Endpoints for 
Animals Used in Biomedical Research, and under the supervision of the Ethics Committee for 
Animal Research of the “Instituto de Salud Carlos III”. 
1.2. Mouse genotyping 
Tail tissue fragments were used for genotyping mice. Tissue was digested overnight at 55°C with 
a lysis buffer containing NaCl 100 mM, Tris-HCl pH 8 20 mM, EDTA10 mM, SDS 0.5% and 
proteinase K (Roche) 400 μg/ml. Tissue lysates were deproteinized with a saturated NaCl 
solution and DNA in the supernatant was precipitated with isopropanol, washed with ethanol 
70% and resuspended in distilled water. PCR reactions were prepared in a 10 μl final volume 
reaction containing 200 μM dNTPs, 1.5 mM MgCl2, 1 μl 10X reaction buffer (Invitrogen), 0.15 
μl Taq polymerase (Platinum Taq, Invitrogen), 0,5 μM of each oligonucleotide primer and 100 
ng genomic DNA. Taq polymerase was activated at 95ºC for 5’ and PCR steps were as follows: 
denaturation at 95ºC 30’’ – annealing at 65ºC 30’’ – elongation at 72ºC 30’’, for 35 cycles. 
The following table contains the primer sequences used and the band sizes generated by each 
allele.  
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Allele name Primer name Sequence (5’3’) Band sizes 
Ewsr1GT 
EW 5arm_2 FW TGCTTCTCAAAGGCTTTACTTT 
wt: 250 
GT: 606 
lox: 444 
KO: 571 
EW neo FW GCCATCACGAGATTTCGATT 
EW exon RE ATCCAAGATTCAGCCAGCAC 
EW 3arm_2 RE AGCAAACAGATGTGAAAACCAG 
Bmi1-CREERT2 
Bmi1CRE A AAAGACCCCTAGGAATGCTC 
wt: 421 
KI: 365 
Bmi1CRE B ACCAGCAACAGCCCCAGTGC 
Bmi1CRE C TAGGCATTAATTGAGATTAACAAACTA 
Fbh1GT 
FB2 5#arm Fw GGCTGTGGTGGTTCATACCT 
wt: 255 
GT: 689 
FB2 exon Re TCTGACCTCCACAAGCTCCT 
FB2 neo Fw GCCATCACGAGATTTCGATT 
ATRSeckel 
Seckel 3’E8 GGAATAAATCCATGGAAGTGAGAGCAT 
wt: 300 
KI: 500 
Seckel neo TCCTCGTGCTTTACGGTATCGCC 
Seckel 5’In7-8 CACTGGCCTCACAGACTTCAGCATG 
CRE 
Cre1 CGATGCAACGAGTGATGAGGTTC 
Tg: 350 
Cre2 GCACGTTCACCGGCATCAAC 
Brca1Δ11 
Brca Del11 B4 CTGGGTAGTTTGTAAGCATGC 
wt: 480 
d11: 650 
Brca Del11 B5 CAATAAACTGCTGGTCTCAGG 
Brca Del11 B6 CTGCGAGCAGTCTTCAGAAAG 
 
1.3. Survival curves 
At least 8 mice per genotype were maintained for each survival analysis. Age of death was 
recorded for each animal and reported on a Kaplan-Meyer curve with GraphPad (Prism 
software). 
1.4. Xenograft assays 
8-10 week-old CB17/lcr-Prkdc scid/Crl mice were used. 1x106 A4573 cells were inoculated 
subcutaneously in the right flank of mice. The growing tumor masses were measured with the aid 
of a Vernier caliper, and tumor volumes were calculated using the formula: (width x (length) 2) 
/2. When tumor volume reached about 100 mm3 mice were randomized into two groups and 
treatment started. 7 mice per group were used. Compound or vehicle was administered via oral 
gavage 5 days per week at a dose of 50 mg/Kg. ATRi was dissolved in 10%NMP (443778; 
Sigma-Aldrich), 50% PEG-300 (202371; Sigma-Aldrich) and 40% H2O. 
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1.5. Inmunohistochemistry 
Tissues were fixed in formalin and embedded in paraffin for subsequent processing. 2.5 μm 
sections were treated with citrate for antigenic recovery and processed for 
immunohistochemistry with the indicated antibodies or for histological staining with cresyl 
violet. Slides were scanned and digitalized with a MIRAX system (Zeiss) for analysis. 
2. Cellular biology 
2.1. Generation of primary MEF cell cultures 
Females were mated with males until vaginal plugs were detected. At day 13.5 post-coitum 
females were sacrificed and embryos were extracted. In a laminar airflow hood, the fetal liver was 
discarded for each embryo and a fragment of tissue was extracted for genotyping (see Mouse 
genotyping). The remaining embryo tissue was chopped with a sterile blade and incubated for 10' 
with 1ml trypsin 0,25%, EDTA (Gibco). The resulting mixture was disaggregated by pipeting 
and trypsin was neutralized with 9ml DMEM 15% FBS. Cell suspension was incubated at 37ºC 
in 5% oxygen atmosphere and medium was changed on the following day. 
2.2. Isolation of splenic B lymphocytes      
Splenectomy was performed in 8 to 12-week-old mice. Whole spleens were disaggregated in 
washing buffer containing 1% bovine seroalbumin (BSA Fraction V, Roche) in PBS. After 
centrifugation, cellular pellets were treated with a hypotonic solution (ACK Lysing Buffer, 
Lonza) for 5' and solution was inactivated by adding washing buffer. Cellular aggregates were 
eliminated through a 40um filter and suspension was centrifuged 5' at 350g. Cellular pellet was 
suspended in 900ul of washing solution and 80ul of anti-CD143-conjugated magnetic beads 
(Miltenyi Biotech) were added. The mix was incubated at 4°C for 15’. Cells were washed, 
suspended in 1ml washing solution and transferred to a magnetic separation column (MS 
Columns, Miltenyi Biotech) attached to a magnetic scaffold (OctoMACS separator, Miltenyi). 
The eluted fraction, containing a pool enriched in B cells, was maintained in culture as indicated 
in the Cell culture section. 
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2.3. Cell culture 
Human Ewing sarcoma, osteaosarcoma and 293T cell lines were grown in Dulbecco’s Minimum 
Essential Media (DMEM, Invitrogen) supplemented with 10% FBS (Lonza) and 1% 
penicillin/streptomycin (Gibco, Invitrogen). MEF were grown in DMEM supplemented with 
15% FBS and 1% penicillin/streptomycin, in a 5% oxygen atmosphere to minimize exposure to 
ROS. For all experiments, MEF were used at a low passage (<3) or after immortalization 
through T121 expression. B cells were cultured in RPMI medium (Euroclone) supplemented 
with 10% FBS, 1% penicillin/streptomycin, glutamine 2mM (Gibco, Invitrogen), non-essential 
aminoacids (Lonza), sodium pyruvate (Gibco, Invitrogen), β-mercaptoethanol 50 mM (Gibco, 
Invitrogen) and HEPES 10 mM (Lonza). 25mg/ml LPS (Sigma-Aldrich) were added to stimulate 
B-cell proliferation and 5 ng/ml IL4 (Gibco) was used to induce immunoglobulin class-switching 
recombination.  
2.4. Cell proliferation curves 
1,25 x 105 cells were plated in a 35mm plate. 2 days later cells were collected, counted, and 1,25 
x105 cells were again plated. The operation was repeated for several passages. The increase in 
population doublings (PDLs) per passage was calculated applying the formula PDLs = log ( nf / 
n0 ) / log2, where n0 is the initial cell number and nf is the final cell number in each passage.  
2.5. Growth inhibition assay 
Cells were grown on clear bottom 96-well plates and treated for 36h with increasing 
concentrations of compounds. Cell Proliferation Kit II-XTT (Roche) was used for assessing 
metabolic activity as a reporter of growth inhibition. The colorimetric reaction product was 
measured with a Wallac 1420 VICTOR2 multilabel plate reader (Perkin Elmer). Dose-response 
curves were generated with Prism software (GraphPad Software) to calculate LD50 values for 
each compound. 
2.6. Metaphase breakage analysis 
Cultured cells were arrested at mitosis with Colcemid (GIBCO/BRL) and fixed with methanol-
acetic acid (3:1). Metaphase spreads were hybridized with a Cy3-labeled telomere-repeat PNA 
probe (Panagene) and stained with DAPI. For immuno-FISH, slides were stained with antibody 
S9.6 after hybridization with telomere-repeat probe following standard immunofluorescence 
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techniques (see Immunofluorescence). Breaks and chromosomal aberrations were quantified 
manually using a Zeiss Imager Z1 fluorescence microscope with an ORCA 1394 camera 
(Hamamatsu) and 40x or 63x objectives (Leica and Zeiss). 
2.7. Immunofluorescence 
Cells were grown on coverslips, fixed with 4% PFA and permeabilized with 0.1% Triton-X100. 
For R-loop detection with S9.6, cells were pre-extracted before fixation as previously described 
(Celeste et al., 2003). Briefly, cells were treated for 5’ with with ice-cold cytoskeleton (CSK) 
buffer containing 10mM PIPES mH6.8, 100mM NaCl, 300mM sucrose, 3mM MgCl2, 1mM 
EGTA, 0.5% Triton X-100. CSK was washed off 3 times with PBS and cells were incubated for 
30’ at room temperature in mSTF fixing solution containing 150mM 2-bromo-2-nitro-1,3-
propanediol, 108mM diazolidinyl-urea, 10mM sodium citrate, 50mM EDTA pH 5.7. Cells were 
washed off 3 times with PBS and blocked with blocking solution containing 2.5% BSA, 0.1% 
goat serum, 0.1% Tween-20 for 30’ at room temperature. Primary antibodies were incubated in 
blocking solution for 1h at room temperature or overnight at 4ºC. Cells were washed 3 times 
with PBS and incubated in blocking solution with secondary antibodies (Alexa Fluor, Invitrogen) 
for 45’. Cells were washed 3 times with PBS, incubated in DAPI for 1’, and mounted on a glass 
slide in Mowiol mounting solution (Sigma-Aldrich). Images were acquired in a Zeiss Imager Z1 
fluorescence microscope with an ORCA 1394 camera (Hamamatsu) and 40x or 63x objectives 
(Leica and Zeiss). 
2.8. High throughput microscopy 
Cells were grown on µClear® bottom 96-well plates (Greiner Bio-One). Immunofluorescence 
was performed using standard procedures (see Immunofluorescence) with the indicated 
antibodies. Analysis of DNA replication by EdU incorporation was done using Click-it reaction 
Kit (Invitrogen) following manufacturer’s instructions. Cell viability assay using HTM has been 
described before (Eguren et al., 2014). Briefly, cells were incubated 1µM TO-PRO®-3 and 5 
ug/ml Hoechst 33342 (Invitrogen) for 30' and subsequently analyzed in vivo. For all assays, 
images were automatically acquired from each well using an Opera High-Content Screening 
System (Perkin Elmer). A 20x or 40x magnification lens was used and images were taken at non-
saturating conditions. Images were segmented using DAPI or Hoechst 33342 signals to generate 
masks matching cell nuclei, from which mean intensity signals for the used markers were 
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calculated with the Acapella Imaging software (Perkin Elmer). Data were represented with the 
use of the Prism software (GraphPad Software). 
3. Molecular biology 
3.1. Southern blotting 
15ug of DNA per sample were digested with an appropriate restriction enzyme for 12h at 37°C 
in a solution containing digestion buffer, BSA 0,1mg/ml and spermidine 2,5mM.  Digested 
DNA was separated by electrophoresis in a 0,8% agarose gel at 40V for 12h. The gel was 
incubated in a 0,25M HCl solution for 15’, washed with distilled water and incubated in 
denaturing solution containing NaOH 0,4M and 0,6M NaCl for 45’. Following a wash with 
distilled water it was incubated in 0,5M Tris-HCl pH 7,5, 1,5M NaCl neutralizing solution for 
30’. DNA was transferred by diffusion in SSC10x to a Hybond N+ nylon membrane (Hybond-
XL, GE Healthcare) during at least 12 hours. UV light (Stratalinker, Stratagene, Agilent 
Technologies) was used to crosslink DNA to the membrane. Membrane was incubated for 2h at 
65ºC in hybridizing solution (0,25m sodic phosphate pH7,2, 1mM EDTA, 1% BSA, 7% SDS, 
0,05 mg/ml salmon sperm (Invitrogen)). Radioactive labeling of the probe was performed as 
follows: 20ng of DNA probe were dissolved in a final volume of 45ul TE buffer and the probe 
was denatured at 99°C. [α-32P] dCTP incorporation reaction was performed with the Random 
Prime System Kit (Stratagene) following manufacturer’s instructions, and radiolabeled probe was 
purified in a Sephadex G-50 Column (ProbeQuant, GE Healthcare). Probe was added to the 
hybridizing solution with the membrane, and incubated overnight at 65°C. The membrane was 
washed twice in SSC 2x 1% SDS for 20’ and once in SSC 0,2x, 0,1% SDS for 20’. Phosphor 
screens were exposed to membranes for 2 to 24h and scanned with a Phosphorimager (Storm 
820; Molecular Dynamics). 
3.2. Western blotting 
For total protein extracts, cells were washed once with PBS and lysed with RIPA buffer (Tris-
HCl 50 mM, pH 7.4, NP-40 1%, Na-deoxycholate 0.25%, NaCl: 150 mM, EDTA 1 mM) 
containing protease and phosphatase inhibitors (Sigma) or with a buffer containing 50 mM Tris 
(pH 7.5), 8 M urea, and 1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate 
(CHAPS). Sub-cellular fractionation extracts were obtained as follows: harvested cells were 
washed twice with ice-cold PBS, resuspended in 180 μl of ice-cold hypotonic lysis buffer 
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(HEPES 10 mM pH 7.9, KCl 10 mM, EDTA 0.1 mM containing protease and phosphatase 
inhibitors), and incubated on ice for 10', followed by addition of 20 μl of Nonidet P-40; after 3' 
at room temperature, cells were vortexed and the cytosolic fraction was obtained by 
centrifugation for 5' at 2,500 × g and collection of the supernatant. The nuclear pellet was 
resuspended in 60 μl of high-salt-concentration extraction buffer (20 mM HEPES, pH 7.9, 0.4 
M NaCl, 1 mM EDTA containing protease and phosphatase inhibitors) and incubated with 
shaking at 4°C for 1 h. The nuclear extract was centrifuged for 5' at 16,000 × g and the 
supernatant (nuclear soluble fraction) stored at −80°C. A volume of (Tris 50mM pH 7.9, urea 
8M, Chaps 1%) was added to the pellet and incubated with shaking at 4ºC for 30' . Chromatin-
bound fraction was obtained by centrifuging for 5' at 16,000 × g and collecting the supernatant. 
Samples were resolved by SDS-PAGE and analyzed by standard Western blotting techniques. 
Protein blot analyses were performed on the LICOR platform (Biosciences).  
3.3. Proteomic analysis 
Cell pellets were extracted and proteins were digested using the FASP protocol (Wisniewski et 
al., 2009). Peptides were labelled with 8-plex iTRAQ reagents and samples were pooled. The 
complex mixture was subjected to IEF fractionation and separation by on-line nano-LC, and 
fractions were analyzed by electrospray MS/MS using a LTQ Orbitrap Velos mass spectrometer 
(Thermo Scientific). Raw files were searched against SwissProt mouse database (23993 entries) 
using Sequest-HT as the search engine through the Proteome Discoverer 1.4 (Thermo Scientific) 
software. Peptides were filtered by Percolator at 1% FDR using the target-decoy strategy. 
3.4. Quantitative RT-PCR 
Total RNA was extracted with Absolutely RNA Miniprep Kit (Agilent) and quantitative RT-PCR 
was performed with Superscript III Platinum One Step qRT-PCR system (Invitrogen) following 
manufacturer's instructions.  
3.5. DRIP-qPCR 
DRIP analysis was performed as described (Ginno et al., 2012). In brief, 5×106 cells were 
collected, washed with PBS, resuspended in 1.6ml of Tris-EDTA (TE) buffer and treated 
overnight with 41.5μl of 20% SDS and 5μl of proteinase K (Roche). DNA was extracted gently 
with phenol–chloroform. Precipitated DNA was spooled on a glass rod, washed with 70% 
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ethanol, resuspended gently in TE and digested overnight with 50U of HindIII, EcoRI, BsrGI, 
XbaI and SspI, 2mM spermidine and BSA. As negative control, half of the DNA was treated 
overnight with 3μl of RNase H (M0297; New England BioLabs). Digested DNA (5μg) was 
bound overnight to 10μl of S9.6 antibody (1mg/ml) in 500μl of binding buffer (10mM NaPO4, 
140mM NaCl, 0.05% Triton X-100) at 4°C. DNA–antibody complexes were 
immunoprecipitated for 2h with Dynabeads Protein A (Invitrogen) at 4°C and washed three 
times with binding buffer. DNA was eluted with 50mM Tris-HCl pH8.0, 10mM EDTA, 0.5% 
SDS, then treated for 45' with 7μl of proteinase K at 55°C and cleaned with phenol–chloroform. 
qPCR was performed at the indicated regions (APOE, RPL13A, ERG1 and SNRPN genes on 
human cells, and AIRN gene on mouse cells). Primer sequences are indicated at the PCR primer 
table. The signal intensity plotted is the relative abundance of DNA–RNA hybrid 
immunoprecipitated in each region, normalized to input values and to the signal at the SNRPN 
negative control region (in human cells). All experiments were performed in triplicate and 
average and standard deviation of results are provided. 
3.6. PCR Primers 
 
Primer name Sequence (5’3’) 
Pre-GT –forward ATGGGCTTCTTGGAATGTTG 
Pre-GT – reverse TGACAGCCTGCTCTTCATTG 
Post-GT –forward AATGCCAATGTGTTTGACGA 
Post-GT – reverse GCAATCTTCGCTTCCAGTTC 
GAPDH – forward GCCACCCAGAAGACTGTGGATGGC 
GAPDH – reverse CATGATGGCCATGAGGTCCACCAC 
45S-forward GAACGGTGGTGTGTCGTT 
45S-reverse GCGTCTCGTCTCGTCTCACT 
18S-5’-jucntion- forward GCCGCGCTCTACCTTACCTACCT 
18S-5’-jucntion- reverse CAGACATGCATGGCTTAATCTTTG 
18S-3’-jucntion- forward AGTCGTAACAAGGTTTCCGTAGGT 
18S-3’-jucntion- reverse CCTCCGGGCTCCGTTAAT 
5.8S-5’-jucntion- forward TACGACTCTTAGCGGTGGATCA 
5.8S-5’-jucntion- reverse TCACATTAATTCTCGCAGCTAGCT 
5.8S-3’-jucntion- forward GAATTGCAGGACACATTGATCATC 
5.8S-3’-jucntion- reverse GGCAAGCGACGCTCAGA 
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28S-5’-jucntion- forward CCGAGACGCGACCTCAGAT 
28S-5’-jucntion- reverse TCCGCTGACTAATATGCTTAAATTCA 
18S- forward GATGGTAGTCGCCGTGCC 
18S- reverse GCCTGCTGCCTTCCTTGG 
5.8S- forward ACTCGGCTCGTGCGTC 
5.8S- reverse GCGACGCTCAGACAGG 
28S- forward GTGACGCGCATGAATGGA 
28S- reverse TGTGGTTTCGCTGGATAGTAGGT 
APOE- forward CCGGTGAGAAGCGCAGTCGG 
APOE- reverse CCCAAGCCCGACCCCGAGTA 
RPL13A- forward GCTTCCAGCACAGGACAGGTAT 
RPL13A- reverse CACCCACTACCCGAGTTCAAG 
EGR1- forward TTCGGATTCCCGCAGTGT 
EGR1- reverse TCACTTTCCCCCCTTTATCCA 
SNRPN- forward TGCCAGGAAGCCAAATGAGT 
SNRPN- reverse TCCCTCTTGGCAACATCCA 
AIRN1- forward GCTGCCTGGCTGATAGACTGTT 
AIRN1- reverse TGCCCACTGCTCTTCAGGTT 
AIRN2- forward TGTGGTTGCTGGGAATTGAA 
AIRN2- reverse GCTCAGCGGTTAAGAGCATTG 
 
3.7. RNA sequencing 
RNA integrity numbers were in the range 9.1-10 when assayed on an Agilent 2100 Bioanalyzer. 
PolyA-positive fraction was purified and randomly fragmented, converted to double stranded 
cDNA and processed through subsequent enzymatic treatments of end-repair, dA-tailing, and 
ligation to adapters as in Illumina's "TruSeq Stranded mRNA Sample Preparation Part # 
15031047 Rev. D". Adapter-ligated library was completed by PCR with Illumina paired-end 
primers (8 cycles). The resulting purified cDNA library was applied to an Illumina flow cell for 
cluster generation and sequenced on an Illumina HiSeq2500 instrument by following 
manufacturer's protocols. For the generation of UCSC gene expression tracks, sequencing reads 
were aligned to human reference transcriptome build mm9 from UCSC using TopHat (v 2.0.10) 
(Trapnell, Pachter e Salzberg, 2009). Mapped transcripts were uploaded into UCSC genome 
browser for visualization. For this purpose the corresponding “accepted_hits.bam” result files 
were pretreated with SAMtools sort and index scripts. 
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3.8. Northern blotting  
Total RNA was extracted with Absolutely RNA Miniprep Kit (Agilent). RNA extracts (5 
µg/well) were separated on a 1% agarose gel prepared with NorthernMax® Denaturing Gel 
Buffer (Ambion) containing 1.2% formaldehyde and run in NorthernMax® Running Buffer 
(Ambion) at 90 V. RNAs were transferred to a Hybond N+ nylon membrane (GE Healthcare) 
and fixed by UV cross-linking. Membranes were prehybridized for 1 h at 45°C in hybridization 
buffer containing 6× SSC, 5× Denhardt’s solution, 0.5% SDS and 1µg/ml salmon sperm DNA. 
The oligodeoxynucleotide probe was labeled with [γ-32P] ATP and incubated overnight on the 
membrane with hybridization buffer at 45°C. After hybridization, membranes were washed twice 
for 10' at room temperature in 2× SSC with 0.1% SDS and once in 1× SSC with 0.1% SDS. 
Phosphor screens were exposed to membranes and scanned with a phosphorimager (Storm 820; 
Molecular Dynamics). Hybridization probe sequences were P1 (5’-acgccgccgctcctccacagtctcccgtt-
3’) and P2 (5’-acccaccgcagcgggtgacgcgattgatcg-3’), described in (Wang et al., 2014). 
4. Antibodies 
Antibodies against Chk1 (NCL, Novocastra), phospho-S345-Chk1 (2348S, Cell Signaling), Rpa32 
(2208, Cell Signaling), phospho-S4/8-Rpa32 (A300-245A, Bethyl), γH2AX (05-636, Millipore), 
Rad51 (sc-8349, Santa Cruz), H2A (#3636, Cell Signaling), IgG1 (553401, BD Pharmingen), 
EWS (sc-6533 and sc-28327; Santa Cruz), FLI1 (sc-356, Santa Cruz), Nucleophosmin (3542, Cell 
Signaling), Fibrillarin (2639, Cell Signaling), S9.6 (kind gift from D. Koshland), α-actin (Sigma) 
and Cdk2 (sc-163, Santa Cruz) were used.  
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RESULTS 
 
PART I: Reducing the toxicitity of RS in mice 
 
One focus of interest in our lab is the molecular basis of RS, and we aim at understanding how 
different factors mediate a cellular response when fork stalling is induced. One of the first 
symptoms of RS upon exposure to HU is the accumulation of ssDNA-RPA at stalled replication 
forks, which is used by the cell machinery as a signaling platform to trigger the RSR (Byun et al., 
2005; Zeman and Cimprich, 2014).  
RS is toxic for cells, one of its outcomes being cell death. In the lab we were interested in 
identifying RS mediator proteins. In this regard, work at the lab of Claus Sorensen suggested a 
possible candidate. They showed that cells depleted from FBH1 failed to accumulate ssDNA-
RPA after HU treatment (Fugger et al., 2009). However, cell proliferation was largely unaffected, 
indicating that absence of ssDNA was not a mere reflection of proliferation arrest, and that 
FBH1 is not required for normal proliferation. Furthermore, FBH1-depleted cells showed a 
better survival and reduced cell death in response to HU (Fugger et al., 2013; Jeong et al., 2013b). 
Consistently, deleterious mutations in the FBH1 gene were enriched in melanoma cell lines 
(Jeong et al., 2013a).  
Provided that RS leads to cancer and ageing (Lecona and Fernandez-Capetillo, 2014), an 
organism with reduced RS levels should be protected from tumorigenesis and/or ageing. This 
rationale has been demonstrated in vivo by the use of transgenic alleles for overexpression of RS-
protective factors in mice. An extra Chk1 allele prolongs the survival of ATRseckel mice, which 
suffer from RS (Lopez-Contreras et al., 2012). Similarly, extra Rrm2 gene dosage (a rate-limiting 
component of the RNR complex, responsible for nucleotide synthesis) extends the lifespan of 
ATRseckel mice and limits CFS breakage (Lopez-Contreras et al., 2015). We hypothesized that if 
FBH1 is a bona-fide promoter of RS, mice suffering from RS might benefit from lacking FBH1. 
1. Generation of an FBH1-deficient mouse strain 
To evaluate the in vivo function of FBH1 we generated an Fbh1 gene-trapped allele (Fbh1GT; 
Figure 10A). A construct carrying a gene-trapping cassette was used to target the endogenous 
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Fbh1 locus in mouse embryonic stem cells and neomycin-resistant clones were screened by 
southern blotting to search for recombinant clones (Figure 10B). Selected clones were used for 
embryonic stem cell aggregation and generation of chimeras, from which a mouse colony was 
established. The efficiency of the gene trapping was assessed by measuring expression levels of 
FBH1 mRNA in primary mouse embryonic fibroblasts (MEF) and in B-cells (Figure 10C). 
Depletion of mRNA was almost complete downstream of the gene trapping cassette as assessed 
by the corresponding primer set pair (“Post-GT”), showing a down regulation of around 98-
99%. Remarkably, a primer set pair upstream of the gene trapping (“Pre-GT”) detected 
decreased mRNA content in the Fbh1GT/GT samples, which might be explained by instability of 
the truncated mRNA. 
Birth ratios showed the expected mendelian distribution (Figure 10D). Adult Fbh1GT/GT mice 
showed a mild decrease in weight that did not reach statistical significance (p value=0.052; n=8 
Fbh1+/+ and 15 Fbh1GT/GT mice; Figure 10E). Both males and females were fertile, looked healthy 
overall, and their lifespan was unaffected (Figure 10F).  
 
Figure 10 
Fbh1 deletion results in viable mice. (A) The Fbh1 gene-trapped allele is depicted. A splice acceptor (SA) cassette followed by a 
polyadenilation signal (pA) interrupt the expression of FBH1 protein at the mRNA level. (B) Southern blot for detection of recombinant ES 
cell colonies after electroporation with the targeting construct. A probe against the 5’ homology arm, mapping to the red-labelled locus in 
(A) was used. Lane 1, wild-type clone; lane 2, recombinant heterozygous clone. (C) Efficacy of the gene trapping was evaluated by 
quantitative RT-PCR with a primer set upstream of the gene-trapping  cassette and a primer set downstream (Pre-GT and Post-GT; 
primers depicted as black arrows in (A)) Data is representative of three independent analyses. (D) Expected and obtained birth ratios of 
Fbh1+/+, Fbh1+/GT and Fbh1GT/GT mice. (E) Weights of Fbh1+/+ (n=8) and Fbh1GT/GT (n=15) mice. (F) Kaplan-Meyer representation of the 
lifespan of Fbh1+/GT (n=7) and Fbh1GT/GT (n=8) mice. 
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2. Phenotypical characterization of Fbh1GT/GT mouse cells 
Next we characterized the mouse strain at the cellular level. Previous studies using human cell 
lines showed attenuated signalling in FBH1-depleted cells in response to RS, including reduced 
RPA phosphorylation and γH2AX, along with an increased survival after RS (Fugger et al., 2013; 
Fugger et al., 2009; Jeong et al., 2013b). We cultured mouse-derived primary cells and subjected 
them to HU treatment. Both RPA phosphorylation (Figure 11A) and γH2AX (Figure 11B) were 
reduced in Fbh1GT/GT cells. However, we did not observe an increase in cell survival or any 
alteration in cell-cycle phase distribution in untreated, HU-treated or ATR inhibitor-treated 
Fbh1GT/GT cells (Figure 11C). Response to ionizing radiation (IR) was also unaltered (Figure 11C). 
 
Figure 11 
FBH1 contributes to signaling RS. (A) Fbh1+/+ and Fbh1GT/GT embryonic stem cells were cultured and treated with HU 1mM for 4 hours 
and collected immediately or after a release into fresh media for 2-hour recovery. Cell extracts were immunoblotted with the indicated 
antibodies. (B) ) Fbh1+/+ and Fbh1GT/GT MEF derived from littermate embryos were treated with HU 2mM for 4 hours, stained with anti-
γH2AX and quantified by high-throughput microscopy (HTM). (C) Primary B cells from ) Fbh1+/+ and Fbh1GT/GT 8 week-old male littermates 
were stimulated with LPS and CD180. 24 hours after stimulation cells were treated with HU 0.5 mM or ATR inhibitor (ATRi) 0.5 µM for 24 
additional hours, or subjected to 4 Gy ionizing radiation (IR) and left in culture for 24 hours. Cells were fixed and stained with propidium 
iodide (PI) and cell cycle profiles were analyzed. Percentage values of sub-G1 populations, corresponding to cell death (regions labeled 
by arrows), are indicated. Data are representative of two independent experiments.  
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Altogether, whereas we observed lower HU-induced γH2AX and RPA phosphorylation in 
Fbh1GT/GT MEF and ES cells, B cells showed no alterations in sensitivity towards HU, ATRi or 
IR. We speculated that Fbh1GT/GT mice might have a subtle phenotype which could be unmasked 
upon conditions of high RS. Similarly to rescue of the lifespan of ATRS/S mice by overexpression 
of RS-protective factors Chk1 or Rrm2 (Lopez-Contreras et al., 2012; Lopez-Contreras et al., 
2015), we wondered wether deletion of FBH1 might rescue the phenotypes of ATRS/S mice to 
some extent. 
3. Impact of FBH1 deficiency on ATR mutant mice 
To investigate whether Fbh1 deletion could have a more profound impact in the presence of RS, 
we took advantage of a mouse model of ATRSeckel previously developed at our lab (Murga et al., 
2009). This model has hypomorphic levels of ATR and suffers from extensive RS and apoptosis 
during embryonary development, which translates into sublethality at birth, a growth defect and 
premature ageing. Following the hypothesis exposed above, if FBH1 mediates accumulation of 
RS, deletion of Fbh1 in ATRS/S mice might rescue its lethality and phenotypes. 
 
Figure 12 
Fbh1 deletion further aggravates the phenotypes derived from excessive RS in ATRS/S mice. (A) Expected and obtained birth ratios of 
ATR+/+, ATR+/s and ATRs/s mice in Fbh1+/GT or Fbh1GT/GT backgrounds. (B) Weights of Fbh1+/GT (n=11) and Fbh1GT/GT (n=5), ATRs/s 8-
week-old mice. (C) Representative picture of four 4-week-old female littermates. (D) Kaplan-Meyer representation of the lifespan of 
Fbh1+/GT (n = 12) and Fbh1GT/GT (n = 10), ATRs/s mice. 
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We generated a cohort of Fbh1+/GT; ATRS/S and Fbh1GT/GT; ATRS/S mice and analyzed their 
phenotypes. Submendelian birth ratios characterystical of ATRS/S mice were not rescued by 
deletion of Fbh1 (Figure 12A). Instead, if anything, dwarfism was further aggravated: Fbh1GT/GT; 
ATRS/S mice were 20% smaller than their Fbh1+/GT; ATRS/S counterparts (Figure 12B) although 
this did not reach statistical significance (p value=0.2). Figure 12C shows a representative litter 
with 4 female littermates at the age of 4 weeks. In spite of that, mean lifespan of Fbh1GT/GT; 
ATRS/S mice was unaltered compared to corresponding counterparts (Figure 12D).   
Together, we conclude that deletion of Fbh1 does not have an overall contribution to suppress 
RS-derived toxicity; on the contrary, if anything, it seems to aggravate the phenotype of ATRS/S 
mice, suggesting that FBH1 might act in signaling a response downstream of RS, rather than 
promoting RS itself. 
4. Role of FBH1 in HR 
FBH1 was proposed as an ortholog of canonical yeast anti-recombinase Srs2 (Chiolo et al., 
2007), and several works in the field support an anti-recombinase role for FBH1 at collapsed 
forks (Chiolo et al., 2007; Fugger et al., 2009; Kohzaki et al., 2007; Lorenz et al., 2009; Morishita 
et al., 2005; Osman et al., 2005). Furthermore, recent work by Ian Hickson and colleagues 
revealed a direct interaction between RAD51 and FBH1. RAD51 binds ssDNA in competition 
with RPA (Liu et al., 2010) and forms a nucleoprotein filament that has a central role in HR-
mediated DSB repair. Hickson and colleagues showed that FBH1 negatively regulates RAD51 by 
displacing it from ssDNA through its helicase-translocase activity, which in FBH1-mutant cells 
results into an increase of chromatin-bound RAD51 (Simandlova et al., 2013). To assess the 
degree of RAD51 binding to chromatin in our model we subjected proliferating B-cells to sub-
cellular fractionation. However, chromatin-bound level of RAD51 in Fbh1GT/GT cells was not 
altered, either in untreated cells or in cells treated with Mitomycin C (a potent DNA crosslinker 
that induces fork stalling and DSB generation) (Figure 13A). It has also been proposed that 
FBH1 ubiquitylates RAD51 by means of its E3 ligase activity, and promotes RAD51 degradation 
as a regulatory mechanism. However, Fbh1GT/GT cells did not show increased RAD51 total levels 
in 3 different cell types or tissues (Figure 13B). 
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In spite of these results we aimed at testing the putative anti-recombinase function of FBH1 in 
vivo. We speculated that depletion of FBH1 might alleviate phenotypes of mice that have a 
deficient HR. For this we used a mouse model with mutant BRCA1. BRCA1 is a pro-
recombinase factor; the Brca1Δ11 allele lacks exon 11, and deficient BRCA1 activity leads to 
impaired HR which causes embryonic lethality and severe cellular phenotypes, including 
premature senescence and chromosomal instability. These deficiencies are suppressed by 
deletion of 53BP1 (Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 2009), and based on 
this 53BP1 was initially proposed to be an anti-recombinase. In our aim to prove an anti-
recombinase role for FBH1, we wondered wether deletion of Fbh1 would mimick 53BP1 in 
rescuing the Brca1Δ11/ Δ11 mouse phenotypes. 
Brca1Δ11/ Δ11 mice succumb at a late stage of embryogenesis and very rarely reach birth. We 
expected that a rescue by Fbh1 deletion might translate into an increase in birth rate of Brca1Δ11/ 
Δ11; Fbh1GT/GT mice. However we did not observe this, as embryo lethality was not significantly 
altered (Figure 14A). Next we assessed the proliferative potential of Brca1Δ11/Δ11; Fbh1GT/GT MEF 
compared to that of Brca1Δ11/Δ11; Fbh1+/GT counterparts. However, and consistent with the 
previous result, premature senescence of Brca1Δ11/Δ11 MEF was not rescued by deletion of Fbh1 
(Figure 14B). Finally we looked at the status of genomic instability in our model by analyzing 
rates of breakage and chromosomal aberrancies in metaphase spreads, but again, Fbh1 deletion 
did not alter the degree of genomic instability characteristic of Brca1Δ11/Δ11 cells (Figure 14C). 
The actual mechanism by which 53BP1 competes with BRCA1 and limits HR is not by directly 
impairing HR, but instead it acts in deviating the repair of a DSB towards the NHEJ pathway 
before the DSB is committed to HR (Bouwman et al., 2010; Bunting et al., 2010; Cao et al., 
 
Figure 13 
Rad51 binding to chromatin or total levels are unaltered in Fbh1GT/GT cells. (A) Sub-cellular fractionation and immunoblotting of primary B 
cell extracts from Fbh1+/+ and Fbh1GT/GT 8 week-old male littermates, 48 hours after stimulation. Cells were left untreated or subjected to 
250 nM mitomycin C (MMC) for 4 hours before processing. Antibodies used are indicated. (B) Total protein extracts of primary B cells, 
mouse testis and primary MEF were immunoblotted for Rad51 total levels. 
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2009). This is evidenced by a repair defect in 53BP1-/- B-cells during immunoglobulin class-
switching (CSR), a process that relies on NHEJ to join distant DSB ends and generate new 
immunoglobulin classes. Analogously to 53BP1, we wanted to test whether FBH1 actually had a 
pro-NHEJ function. To assess this we subjected proliferating B-cells to stimulation with IL4 and 
measured rates of class-switching to IgG1. However, no class-switching defect was observed in 
Fbh1GT/GT cells (Figure 14D). Taken together, FBH1 in vivo does not negatively regulate Rad51 
levels or binding to chromatin, and it does not oppose an HR-promoting factor such as BRCA1 
at the organism level. 
 
Figure 14 
FBH1 does not show an anti-recombinase role. (A) Expected and obtained birth ratios of Brca1+/+, Brca1+/Δ11 and Brca1Δ11/Δ11 mice in 
Fbh1+/+ or Fbh1GT/GT backgrounds. (B) Growth curves of Fbh1+/GT and Fbh1GT/GT MEF in Brca1+/+ or Brca1Δ11/Δ11 backgrounds. (C) 
Analysis of breakage and aberrations in Fbh1+/GT and Fbh1GT/GT MEF metaphases in a Brca1+/+ or Brca1Δ11/Δ11 background. Data are 
representative of 2 independent experiments. (D) Class-swithching to IgG1 in primary B cells from Fbh1+/+ and Fbh1GT/GT 8 week-old male 
littermates after stimulation with IL4 during 96 hours. Percentages of IgG1-positive populations are indicated. Data are representative of 2 
independent experiments. 
 
Overall, we could not demonstrate an RS-promoting role for FBH1, as its deletion did not 
protect cells or mice from RS. As opposed to previous results by other groups, the effects of 
Fbh1 deletion in vivo are very mild. In regards to an HR-regulatory role, no impact of Fbh1 
deletion on the regulation of RS-derived HR was observed either. Therefore, the contribution of 
murine FBH1 to the RSR at the organism level remains elusive.  
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PART II: Exploring the role of RS in cancer and age-related 
diseases 
1. Targeting RS as a strategy to treat cancers 
We have previously reported that tumor types with high RS are specially dependent on a 
proficient RSR, and inhibiting ATR or CHK1 in these tumors efficiently abrogates tumoral 
growth (Murga et al., 2011; Schoppy et al., 2012). 
Work in our lab demonstrated that the process of tumoral transformation generates RS, and that 
an extra allele of CHK1 reduces RS levels during this process, thereby facilitating transformation 
(Lopez-Contreras et al., 2012; Schulze et al., 2014). Accordingly, tumors tend to gain CHK1 
expression levels in order to protect themselves from the RS arising during transformation and 
tumoral growth (Bartek et al., 2012; Sarmento et al., 2014). Based on this, we used CHK1 
expression levels as a surrogate marker for RS, and interrogated the Cancer Cell Line 
Encyclopedia (CCLE) on CHK1 expression levels across different human tumoral cell lines as a 
means to identify new tumor types that might be suitable to our strategy (Figure 15).  
 
 
Figure 15 
CHK1 expression levels across human tumoral cell lines. Ewing sarcoma is the second solid tumor with highest CHK1 expression levels, 
below mesothelioma. Above them, 8 hematologic tumors occupy the highest places in CHK1 expression across all human tumors. Gene 
expression data extracted from the Cancer Cell Line Encyclopedia (http://www.broadinstitute.org/ccle) 
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Expectedly, the tumor types with highest CHK1 levels were lymphomas and leukemias, which 
have been demonstrated to have high RS levels and hypersensitivity to inhibition of the RSR 
(Murga et al., 2011; Schoppy et al., 2012). Hematologic cancers aside, Ewing sarcoma is the 
second solid tumor type with highest RS (below mesothelioma). This matched our initial 
observation that the high degree genomic instability in Ewing sarcoma but low SNP and point 
mutation rate described for pediatric cancers were reminiscent of RS in Ewing sarcoma 
(Alexandrov et al., 2013; Ferreira et al., 2008; Ohali et al., 2004). 
2. Ewing sarcoma-derived cell lines have RS and are sensitive to 
ATR inhibition 
2.1. Ewing sarcoma cell lines have increased RS 
To verify a signature of RS in Ewing sarcomas we used a panel of Ewing sarcoma cell lines (ES 
cell lines) and non-ES, osteosarcoma cell lines, as well as human primary cells. Consistent with 
CCLE data (Figure 15), ES cell lines present increased levels of CHK1 protein, and these 
correlate with increased γH2AX levels (Figure 16A). Whereas γH2AX is a common mark 
signalling different types of DNA damage, a specific pattern with pannuclear staining is 
characteristical of RS (Syljuasen et al., 2005; Toledo et al., 2011). To assess this we used a tissue 
 
Figure 16 
ES cell lines have increased RS. (A) Protein extracts from osteosarcoma cell lines, ES cell lines and human primary cells were 
immunoblotted with the indicated antibodies. (B) Immunohistochemistry for γH2AX staining was performed on human tumoral samples of 
rhabdomyosarcoma (RMS), neuroblastoma (NB) and Ewing sarcoma (upper panels); and on mouse xenografts generated with cell lines 
derived from human RMS (cell line SJRH), NB (cell line SKNAS) and Ewing sarcomas (cell lines A673, TC71, A4573) (lower panels). 
Scale bars, 20 µM. 
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microarray containing samples from Ewing sarcoma and non-Ewing sarcoma primary tumors, 
and a tissue microarray containing murine xenograft samples generated from ES and non-ES cell 
lines (Figure 16B). We observed not only an abundant γH2AX signal, but also a strong 
pannuclear staining pattern both in Ewing sarcoma primary tumors and in ES cell line-derived 
xenografts, consistent with RS. Because ES cell lines consistently showed a particular signature 
of RS, we wondered whether targeting the RSR in Ewing sarcomas could serve to selectively kill 
tumoral cells. 
2.2. ES cell lines are hypersensitive to ATR inhibition 
To test the efficacy of ATR inhibition in Ewing sarcoma we subjected ES cell lines and 
osteosarcoma cell lines to a prolonged treatment with vehicle or ETP-46464 (an ATR inhibitor 
developed in our lab in collaboration with the Experimental Therapeutics Unit at CNIO (Toledo 
et al., 2011); from now on, ATRi). Analysis of the cell cycle profiles showed a specific toxicity 
towards ES cell lines, which presented significative sub-G1 populations indicative of cell death, 
whereas osteosarcoma cell lines remained largely unaffected (Figure 17A). 
Next we assessed the in vitro sensitivity of ES cell lines and control cells to ATR inhibition. 
Importantly, we assayed two independent ATR inhibitors: ATRi and AZ-20 (Astra Zeneca). We 
also assayed sensitivity to temozolomide (TMZ), one chemotherapeutic agent currently used in 
Ewing sarcomas, and to Olaparib (a PARP1 inhibitor), as ES cell lines were recently identified as 
being sensitive to PARP inhibition (Garnett et al., 2012) and Olaparib is now being explored as 
an alternative to TMZ (Brenner et al., 2012). We determined the 50% lethal dose (LD50) values 
for a panel of ES and non-ES sarcoma cell lines, as well as for primary cells, subjected to 
treatment with ATR inhibitors, Olaparib or TMZ (Figure 17B and C). Both ATR inhibitors were 
highly toxic to ES cells. ATRi showed LD50 values to ES cell lines more than 10-fold lower than 
to non-ES cell lines, and close to 1000-fold lower compared to primary human cells. LD50 for 
AZ-20 was over 4-fold lower in ES cells than in non-ES cancer cells, and around 10-fold lower 
compared to primary cells. Remarkably, whereas Olaparib was also toxic to ES cells, it was so 
within the micromolar scale. In contrast, both ATR inhibitors were effective at the nanomolar 
scale. Finally, for all cell lines, LD50 values to TMZ were out of the assayed dose range (3nM to 
100µM) and above that, and we could only state LD50s being above 100µM for all cell lines. 
Therefore, we could not determine whether a preferential toxicity of TMZ exists towards ES 
cells. 
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Figure 17 
ES cell lines are hypersensitive to ATR inhibition. (A) ES cell lines and osteosarcoma cell lines were subjected to 150 nM ATR inhibitor 
(ATRi) treatment for 72h or left untreated. Cells were collected and processed for flow cytometry using propidium iodide as an indicator of 
DNA content. Cell cycle profiles are displayed. (B) Human primary cells (HuVEC, HFF1, HFF2; blue), osteosarcoma cell lines (U2OS, 
SAOS-2; blue) and ES cell lines (A673, A4573, TC71, SK-ES-D, TTC466; red) were treated with increasing concentrations of ATRi for 
24h. A viability colorimetric assay based on cellular metabolic activity was used to calculate LD50 values for each cell line. Absorbance, 
proportional to cell viability, is plotted against ATRi concentration for each cell line. (C) The assay was repeated for AZ-20 (an independent 
ATR inhibitor), Olaparib (a PARP-1 inhibitor) and temozolomide (TMZ). LD50 values for all compounds are listed. 
 
2.3. ATRi impairs tumor growth in Ewing sarcoma xenografts 
Next we asked whether ATR inhibition would have an impact on tumoral growth in vivo. For this 
we injected A4573 ES cells subcutaneously to immunodeficient mice to generate ES xenografts, 
and treated mice with ATR inhibitors or vehicle. We used two independent ATR inhibitors: AZ-
20 and MSC253, an in vivo derivative of ETP-46464 that has been licensed to Merck for clinical 
developments. Xenograft growth was greatly abrogated upon treatment with ATR inhibitors, 
most strikingly with MSC253, as depicted in Figure 18A. Representative tumours at day 11 after 
treatment initiation are shown (Figure 18B). Importantly, tumours treated with ATR inhibitors 
undergo massive accumulation of RS as evidenced by pannuclear γH2AX staining, which was 
evident in xenograft tissue sections taken 48 hours after treatment initiation (Figure 18C). Of 
note, chemotherapeutic treatments frequently consist of multiple drug combinations, and 
clinical/pre-clinical trials are addressed accordingly. The fact that ATR inhibitors (especially 
MSC253) efficiently abrogate tumoral growth as monotherapy suggests a great potential for an 
eventual translation into the clinics. 
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Figure 18 
ATR inhibition abrogates tumoral growth of ES cell line-derived xenografts. (A) 1x106 cells from A4573 ES cell line were subcutaneously 
injected into immunodeficient (SCID) mice. As soon as tumors were palpable (around 50 mm3) treatments with ATR inhibitors AZ20, 
MSC253, or vehicle were started. 50 mg/Kg of compound were administered 5 days per week (Monday to Friday) with an intragastric 
probe. Tumor sizes were measured daily with a caliper, and tumor volume was inferred through the formula (width*(length)2)/2. Mean 
tumoral growth is plotted for each treatment group. Vehicle, n=7; AZ20, n=7; MSC253, n=7. (B) representative tumors from each group at 
day 11 after treatment start. (C) Tumoral tissue samples extracted at day 2 after treatment start and processed for IHC with anti-γH2AX. 
Scale bars, 30 µM. 
 
Taken together, in sections 1 and 2 we learned that Ewing sarcomas suffer from high RS levels. 
Consistently, ES cell lines presented in vitro and in vivo sensitivity towards ATR inhibition. In the 
following sections we asked about the origin of RS in Ewing sarcomas. 
3. Expression of EWS/FLI1 leads to RS and ATRi hypersensitivity 
To verify that ATRi sensitivity was not a particularity of the ES cell lines in use, we asked 
whether expression of the translocation product EWS/FLI1 is sufficient to drive accumulation 
of RS and sensitization towards ATR inhibition. In a work mainly developed by Isabel Morgado 
at our lab, we used a transgenic mouse model for conditional expression of the EWS/FLI1 
fusion protein (Figure 19A) (Lin et al., 2008), and we cultured wild-type (WT) and CRE-
inducible EWS/FLI1 (EWS/FLI1ind) MEF, both expressing a CREERT2 recombinase dependent 
on hydroxytamoxifen (OHT) (Figure 19B). After induction with OHT, cell cycle profiles were 
analyzed. EWS/FLI1-expressing MEF showed an increase in the sub-G1 population compared 
to WT MEF, which evidenced a sensitization towards ATR inhibition, consistent with increased 
RS levels (Figure 19C). Interestingly, for other RS-inducing oncogenes such as MYC or H-RAS, 
acceleration of the replication rate has been described as the source of RS. Conversely, 
EWS/FLI1 expression did not promote acceleration of replication, rather the contrary (Figure 
19D), thereby suggesting that EWS/FLI1 induces RS by other means different than acceleration 
of replication. 
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Figure 19 
Expression of EWS/FLI1 leads to accumulation of RS and sensitizes to ATR inhibition. (A) Transgenic allele for inducible expression of 
EWS/FLI1. Adapted from (Lin et al., 2008). A chicken β-actin promoter and a CMV enhancer control expression of the transgene. An 
EGFP-polyA cassette prevents expression of EWS/FLI1. Upon CRE-mediated excission of the EGFP-polyA cassette, EWS/FLI1 
expression is enabled. (B) Wild-type (WT) and transgenic (EWS/FLI1ind) MEF, both expressing CREERT2, where generated. Protein 
extracts with and without a 48h-induction with OHT were blotted for detection of EWS/FLI1 expression. (C) OHT-induced, WT and 
EWS/FLI1ind MEF were untreated or treated with ATRi 1µM for 48h. Cells were collected and processed for flow cytometry with 
propidium iodide staining. Cell cycle profiles are displayed and relative percentages of Sub-G1 populations (red) are indicated. (D) Wild-
type MEF were infected with an empty vector(pBabe-empty), a vector for EWS/FLI1 expression (pBabe-EWS/FLI1) or a vector for c-Myc 
expression. 48h after infection cells were incubated with EdU for 30min and processed for HTM-mediated quantitative detection of EdU 
incorporation. All experiments were performed by Isabel Morgado. Data in B and C are representative of three independent experiments. 
In D, center lines indicate mean values. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
4. EWS protein as a suppressor of RS 
The EWS/ETS translocation event and its fusion product were postulated as drivers of 
tumorigenesis, based on the oncogenic activity described for EWS/FLI1 (May et al., 1993a; May 
et al., 1993b) and its direct alteration of the cellular expression pattern (Kauer et al., 2009; Riggi 
et al., 2008). Nonetheless, genetically, the translocation event also implies the truncation of 
EWSR1 gene at the affected allele. Therefore two genetic modifications occur upon 
translocation: a) the generation of a novel fusion product and b) the loss of one copy of EWSR1. 
Because the latter might imply a loss of function of EWS, we wondered whether this has an 
actual contribution to the pathology of Ewing sarcoma. Furthermore, loss of function could be 
enhanced if considering a hypothetical dominant-negative effect of EWS/FLI1 over the 
remaining wild-type EWS protein, an idea that has already been suggested (Spahn et al., 2003).  
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In this context we wondered whether loss of EWS function, analogously to expression of 
EWS/FLI1, also results in accumulation of RS and sensitization to ATR inhibition; that is, if 
EWS has a protective role against RS (Figure 20). In fact, several evidence in the literature point 
to a role for EWS in  genome surveillance; first, a knockout mouse model for Ewsr1 
phenotypically resembles the ATRS/S mouse (a mouse model of RS) in that both present 
craneofacial abnormalities, sub-lethality, reduced body weight and reduced lifespan (Li et al., 
2007). Second, EWS depletion in germinal cells drives XY asynapsis, which is prevented by 
ATR. Third, EWS interacts with BARD1 which, in complex with BRCA1, is involved in the 
repair of broken replication forks to promote replication restart (Spahn et al., 2002). Fourth, 
EWS is required for resistance to CPT, a TopoI inhibitor that generates RS (O'Connell et al., 
2010). To dissect the relative contributions of the two genetic contidions present in Ewing 
sarcoma, namely the EWS/ETS fusion product and EWS loss of function (Figure 20), we 
decided to generate a mouse model for the genetic deletion of Ewsr1 gene. 
 
Figure 20 
Dissecting the genetic contributions of 
EWS/FLI1 and EWS loss of function to 
Ewing sarcoma. Ewing sarcoma patients 
suffer a translocation between EWS and an 
ETS transcription factor (most frequently 
FLI1), resulting in two genetic conditions: 
gain of EWS/FLI1 fusion product and loss of 
EWS. We have used mouse models for 
expression of EWS/FLI1 and for deletion of 
EWS protein in order to dissect the 
contributions of the two genetic conditions 
to the phenotypes observed in Ewing 
sarcomas and in ES cell lines. 
5. Generation of a mouse model for the deletion of Ewsr1 
We used a “gene-trap first” construct from the European Consortium targeting the Ewsr1 locus. 
The construct contained a floxed promoter-driven neo cassette and an IRES:lacZ trapping 
cassette inserted into intron 3 (Figure 21A). The splice acceptor (SA) and the IRES:LacZ-polyA 
disrupts gene function and promotes early termination or gene trapping of the transcript 
(Ewsr1GT allele). Exon 4 is floxed. FLP recombination mediates excision of the neo and 
IRES:LacZ cassette and converts the “gene-trap first” allele to a conditional allele, restoring gene 
activity (Ewsr1lox allele). CRE recombination results in excision of the floxed exon 4 to generate a 
frameshift mutation that triggers nonsense mediated decay of the resulting transcript.  
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Mouse embryonic stem cells were electroporated with the targeting construct and neomycin-
resistant clones were screened by southern blotting to search for recombinant clones (Figure 
21B). Selected clones were used for embryonic stem cell aggregation and generation of chimeras, 
from which a mouse colony was established in a B6-129Sv mixed genetic background. Efficacy 
of the gene-trapping was validated by western blotting on MEF culture protein extracts with an 
antibody against EWS protein (Figure 21C).   
 
Figure 21 
Description of the Ewsr1 "gene-trap first" allele. (A) A construct targeting the Ewsr1 endogenous locus was provided by the Euroean 
Consortium. The construct contains an IRES-LacZ gene-trapping cassette and a promoter-driven neo cassette inserted in intron 3 and 
flanked by FRT sites, and two loxP sites flanking exon 4. An allele bearing the full construct works as a gene-trap, and leads to 
constitutive deletion of EWS protein. FLP-mediated recombination of the FRT sites promotes excision of the LacZ and neo cassettes, 
thereby converting the genetrap allele to a conditional allele and restoring gene activity. Subsequent CRE-mediated excision of exon 4 
generates a frameshift mutation, knocking out Ewsr1 gene. The full construct (vector) was electroporated into embryonic stem cells. (B) 
Neo-resistant clones were screened by southern blot to identify recombinants, and a probe hybridizing to the 3' homology arm was used 
(labeled in red in panel A). (C) Deletion of EWS protein in homozygous Ewsr1GT/GT MEF was validated by western blotting. 
 
5.1. EWS deletion is embryonic lethal and results in embryonic RS 
The previously reported Ewsr1-knockout mouse model presented mendelian birth ratios and a 
high rate of postnatal lethality prior to weaning (Li et al., 2007) In our model, maybe due to a 
more restrictive genetic background, homozygous deletion of the Ewsr1 gene was lethal already 
at the late embryonic stage. Whereas at day E13.5 post-coitum the ratios of homozygous and 
heterozygous embryos matched the expected mendelian ratios, few Ewsr1GT/GT pups were born 
and they were all invariably dead within few hours after birth. We next analyzed late-stage 
embryos in order to look for alterations that could explain the embryonic lethality of Ewsr1GT/GT 
mice. 
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The highly proliferative erythropoietic compartment is especially sensitive to RS; a number of 
mouse models that suffer from RS present an activated DDR in this cellular population, and 
suffer from anemia due to depetion of erythropoietic progenitors (Murga et al., 2009; Shima et 
al., 2007). Strikingly, some Ewsr1GT/GT E18.5 embryos presented a pale appearance suggestive of 
anemia, and a smaller size (Figure 22A). EWS deletion in all tissues was validated by full-embryo 
IHC (Figure 22B). Consistent with anemia, blood analyses of the embryos revealed a defect in 
erythropoiesis with decreased red blood cell counts, but unaltered white blood cell counts 
(Figure 22C). Pannuclear γH2AX-positive cells were detected in all tissues in Ewsr1GT/GT embryos 
(Figure 22D), and were particularly high at the embryonic liver, where embryonic erythropoiesis 
takes place (Figure 22E, F). Together, absence of EWS promotes the accumulation of RS during 
embryonic development. This is particularly abundant at the erythropoietic compartment and is 
the probable cause of anemia in Ewsr1GT/GT embryos, which in turn is likely to cause late-stage 
embryo lethality. 
 
Figure 22 
Deletion of EWS leads to accumulation of RS and anemia at the late-embryo stage. (A) Representative picture of E18.5, Ewsr1+/+ and 
Ewsr1GT/GT littermate embryos. (B) IHC on Ewsr1+/+ and Ewsr1GT/GT E18.5 embryos for detection of EWS. (C) Blood analyses of Ewsr1+/+ 
and Ewsr1GT/GT E18.5 embryos including red blood cell (WBC) counts and white blood cell (WBC) counts. Data are representative of 5 
independent analyses. (D and E) IHC for γH2AX detection at skeletal muscle (D) and liver (E) tissues of E18.5 Ewsr1+/+ and Ewsr1GT/GT 
littermate embryos. Scale bars, 40 µM. Insets (squares) are provided at high magnification to illustrate the nature of the signal. Scale bars, 
12 µM. (F) Quantification of γH2AX-positive cells in D and E. Data in D, E and F are representative of 3 independent experiments. 
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6. RS and sensitivity to ATRi in EWS-deficient cells 
To further explore the role of EWS in RS, we cultured MEF derived from Ewsr1+/+ and 
Ewsr1GT/GT E13.5 littermate embryos. Notably, Ewsr1GT/GT MEF proliferated significantly slower 
and reached senescence prematurely (Figure 23A, B). 
6.1. Ewsr1GT/GT MEF show increased levels of RS 
We looked at RS levels on MEF. Untreated Ewsr1GT/GT cells presented a moderate increase in 
γH2AX compared to wild-type counterparts (Figure 23C, D). As exposed above, ATR responds 
 
Figure 23 
Absence of EWS in MEF leads to RS and premature senescence. (B) Ewsr1+/+ and Ewsr1GT/GT primary MEF were incubated with EdU for 
30min and processed for HTM-mediated quantitative detection of EdU incorporation. Data are representative of 5 independent 
experiments. (C) Growth curves of Ewsr1+/+ and Ewsr1GT/GT primary MEF. (D) Ewsr1+/+ and Ewsr1GT/GT primary MEF were untreated or 
treated with ATRi 5 µM for 4h and processed for HTM-mediated quantification of γH2AX. A threshold (grey horizontal line) was set to 
define subpopulations of γH2AX-positive cells. (E) Graphic representation of γH2AX-positive cells in D. (F) Ewsr1+/+ and Ewsr1GT/GT MEF 
were untreated or treated with CPT 100nM for 16h and processed for HTM-mediated quantification of γH2AX. A threshold (grey horizontal 
line) was set to define subpopulations of γH2AX-positive cells. (G) Graphic representation of γH2AX-positive cells in F. Data in D and E 
are representative of 3 independent experiments. 
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to and limits RS; therefore, a mechanism to highlight an underlying RS in growing cells is to 
inhibit ATR. Based on this we challenged cells with ATRi. Ewsr1GT/GT cells presented a 
remarkable accumulation of γH2AX in response to ATRi, indicative of increased RS (Figure 
23C, D). ES cell lines were identified as sensitive to topotecan and irinotecan (clinical derivatives 
of CPT) (Barretina et al., 2012), and drug combinations involving these compounds are currently 
being explored for chemotherapy (Kurucu et al., 2015). Because of its clinical relevance, we 
challenged cells with CPT and, again, Ewsr1GT/GT showed a significative increase in γH2AX 
(Figure 23E, F). This was consistent with the previously described requirement of EWS for 
resistance to CPT (O'Connell et al., 2010), and further supports the hypothetical dominant-
negative effect of EWS/FLI1 over EWS, as Ewing sarcomas are also sensitive to CPT. 
Importantly, the decreased proliferation rate of Ewsr1GT/GT cells (Figure 23A, B) suggests that we 
might be underestimating the levels of RS detected in these cells; considering this, the increase in 
γH2AX in Ewsr1GT/GT cells is even more significant than what observed values suggest. In the 
same line, the decreased proliferation rate of Ewsr1GT/GT cells might contribute to mask any 
further increase in γH2AX when these cells are growing in basal conditions. 
6.2. Ewsr1GT/GT MEF have increased genomic instability 
Since RS leads to genomic instability (Barlow et al., 2013; Burrell et al., 2013; Costantino et al., 
2014; Dereli-Oz et al., 2011), we wondered whether this took place in Ewsr1GT/GT MEF. We 
prepared Ewsr1+/+ and Ewsr1GT/GT metaphase spreads and quantified breaks and other 
chromosomal aberrations. Although not reaching statistical significance, the breakage ratio in 
Ewsr1GT/GT MEF was increased (Figure 24A, B). Genomic instability frequently results in 
chromosomal segregation problems during mitosis and subsequent accumulation of micronuclei, 
DNA bridges and other nuclear aberrations that are visible in interphasic nuclei. We quantified 
micronuclei and DNA bridges and found increased nuclear aberrations in Ewsr1GT/GT MEF 
(Figure 24C). In Figure 24D cells with micronuclei (left panel) and DNA bridges (right panel) are 
shown to illustrate the nature of this kind of aberrations. These observations suggested that an 
EWS loss of function in Ewing sarcomas might contribute to the described pattern of genomic 
instability in Ewing sarcomas. 
  RESULTS 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
70 
 
Figure 24 
Ewsr1GT/GT MEF have increased genomic instability. (A) Ewsr1+/+ and Ewsr1GT/GT MEF metaphases were spreaded on glass slides and 
stained with DAPI. Quantification of chromosomal breaks and aberrations is plotted. (B) Example Ewsr1+/+ and Ewsr1GT/GT metaphases 
are shown. Red arrows indicate chromatid breaks. (C) Untreated Ewsr1+/+ and Ewsr1GT/GT MEF cultures were fixed and stained with DAPI. 
Quantification of micronuclei, DNA bridges and other nuclear aberrations is plotted. (D) Example interphasic nuclei with aberrations are 
shown. White arrows indicate micronuclei (left panel) and DNA bridges (right panel). 
 
 
6.3. Ewsr1GT/GT MEF are hypersensitive to ATRi 
Based on the increased RS and genomic instability detected in Ewsr1GT/GT MEF, we wanted to 
assess whether EWS deletion sensitized cells to ATR inhibition. Analogously to EWS/FLI1-
expressing MEF, cell cycle profiling revealed an increased sub-G1 population in Ewsr1GT/GT 
MEF after ATR inhibition, indicating increased cell death and hypersensitivity to ATRi (Figure 
25A). We further characterized hypersensitivity by measuring the uptake of intravital stain 
ToPRO3 on live cell cultures. The percentage of ToPRO3-positive cells, reflecting dead cells, 
was significantly higher in Ewsr1GT/GT cells both in untreated and in ATRi-treated conditions 
(Figure 25B and C). 
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Figure 25 
Ewsr1GT/GT  MEF are hypersensitive to ATR inhibition. (A) Ewsr1+/+ and Ewsr1GT/GT primary MEF were untreated or exposed to ATRi 5µM 
for 48h and processed for flow cytometry with propidium iodide as a marker of DNA content. Cell cycle profiles are depicted, and sub-G1 
relative populations (labeled in red) are quantified. (B) Ewsr1+/+ and Ewsr1GT/GT primary MEF were untreated or exposed to ATRi 2.5µM 
for 8h. ToPRO3 intravital stain was added before in vivo HTM-mediated analysis of ToPRO3 incorporation in cells. A threshold (grey 
horizontal line) was set to define subpopulations of ToPRO3-positive cells. (C) Quantification of ToPRO3-positive, dead cells in 
experiment B. Data in A, B and C are representative of 3 independent experiments. 
 
Taken together, we showed that both the expression of EWS/FLI1 and the deletion of EWS 
generate RS and genomic instability, and sensitize cells to ATR inhibition, phenotypes that are 
observed in Ewing sarcomas (section 2). Given that both conditions lead to decreased replication 
(Figures 19D and 23A), the reasons by which loss of EWS function leads to RS remained 
unexplained and demanded further investigation. 
6.4. The RSR is proficient in Ewsr1GT/GT MEF 
One of the proposed roles of EWS is in splicing. Paronetto and colleagues described a splicing 
defect in EWS-deficient cells that affected alternative splicing of DDR genes in response to 
DNA damage (Paronetto et al., 2011). To test whether Ewsr1GT/GT MEF sensitivity to RS-
inducing agents was due to a deficient RSR we treated MEF with HU and analyzed markers of 
RSR activation. Ewsr1GT/GT MEF presented a proficient RSR, as demonstrated by efficient 
phosphorylation of RPA and CHK1 (Figure 23A). We next performed RNA sequencing of 
Ewsr1+/+ and Ewsr1GT/GT MEF. As a validation of the sequencing process, Ewsr1 mRNA 
appeared decreased in Ewsr1GT/GT MEF (Figure 26B, upper panel). We looked at distinct DDR 
and RSR genes and found no significant variations in exon usage between Ewsr1+/+ and 
Ewsr1GT/GT MEF (Figure 26B, lower panel), suggesting that the hypersensitivity of Ewsr1GT/GT 
MEF is not due to splicing defects. 
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Figure 26 
Ewsr1GT/GT  MEF do not show deficiencies in the RSR or alterations in splicing. (A) Ewsr1+/+ and Ewsr1GT/GT primary MEF were untreated 
or treated with HU 2mM for 4h, and subsequently processed for protein extraction. Western blotting was performed with the indicated 
antibodies. (B) Exon usage at Chek2 gene is not affected in Ewsr1GT/GT MEFs. RNA from Ewsr1+/+ and Ewsr1GT/GT MEF was used for RNA 
sequencing. Expression tracks were generated and uploaded to the UCSC browser. Expression levels for Ewsr1 and Chek2 in Ewsr1+/+ 
and Ewsr1GT/GT MEF are shown. Upper panel, Ewsr1; lower panel, Chek2.Cristina mayor performed the sequencing analysis and 
expression track generation. 
 
7. R-Loops and RS 
Frequently, RS leads to replication fork stalling and helicase-polymerase uncoupling which 
generates long threads of ssDNA (Byun et al., 2005). A common marker used to define the 
presence RS is the detection of ssDNA itself, or RPA foci accumulation, which form on ssDNA. 
However, even though we observed increased ATRi sensitivity and high pan-nuclear γH2AX 
levels, we were unable to detect increased RPA foci formation in Ewsr1GT/GT or in EWS/FLI1-
expressing cells either in untreated or in RS-challenging conditions (data not shown). Taking into 
account the proliferative defect in these cells (Figure 19D and Figure 23A), we considered 
sources of RS that do not involve fork uncoupling (and therefore would not promote RPA foci 
accumulation) and that are not necessarily dependent on a deregulation of the cell cycle 
progression. This is the case for R-loops. 
R-loops are three-stranded nucleic acid structures composed of an RNA:DNA hybrid and a 
displaced DNA strand (Aguilera and Garcia-Muse, 2012). These structures arise when newly 
synthesized RNA re-hybridizes with its template DNA (Figure 27A). Collisions of replication 
forks with persistent R-loops are a source of RS (Figure 27B) (Aguilera and Garcia-Muse, 2012). 
R-loop formation occurs with special frequency at sites with high transcription rates such as the 
nucleolus (El Hage et al., 2010). The nucleolus, which is composed of ribosomal DNA (rDNA), 
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hosts the transcription of the highly abundant ribosomal RNA (rRNA), accounting for 80% of 
cellular transcription. Nucleoli accumulate R-loops, as observed in cultured wild-type U2OS cells 
stained with S9.6, an antibody that specifically recongnizes RNA:DNA hybrids (Figure 27C). 
This accumulation is dependent on active transcription as evidenced by loss of S9.6 signal upon 
inhibition of RNA polymerase I (RNAPI) by treatment with a low dose of actinomycin D (5nM), 
which selectively inhibits RNAPI but not RNAPII (Figure 27D). Importantly, R-loops are not 
restricted to nucleoli, as they have also been described to occur at sites of RNAPII transcription 
(Ginno et al., 2012; Wongsurawat et al., 2012).  
R-loops pose a threat to replication as they are physical obstacles to fork progression, and active 
mechanisms exist to prevent collisions. RNase H removes R-loops by endonucleolytical cleavage 
of the RNA fraction (Huertas and Aguilera, 2003) and several helicases, including Pif1, DHX9 
and Senataxin can unwind the RNA:DNA hybrids (Alzu et al., 2012; Boule and Zakian, 2007; 
Chakraborty and Grosse, 2011; Kim et al., 1999; Yuce and West, 2013). 
 
Figure 27 
R-loops are transcription-associated RNA:DNA hybrid structures that interfere with replication and generate RS. (A) RNA:DNA hybrids 
termed R-loops arise as newly-synthesized transcripts anneal to template DNA. (B) A series of conflicts invoving R-loops can occur that 
generate RS upon collision of an approaching replication fork with (a) unrepaired DNA lesions in the ssDNA displaced strand, (b) the 
RNA:DNA hybrid itself, (c) an RNAP putatively trapped at the transcription site by the R loop, (d) R loop-mediated torsional stress. Panels 
A and B are adapted from (Aguilera and Garcia-Muse, 2012). (C) S9.6 antibody specifically recognizes RNA:DNA hybrids and labels R-
loops, which are enriched at the nucleoli. (D) Inhibition of transcription with ActD 5nM for 2h abrogates R-loop accumulation.  
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The structural determinants and described functions of EWS are compatible with a role in R-
loop metabolism. First, EWS was originally described as an RNA and DNA binding protein, and 
interaction with several partners is dependent on the presence of RNA (Pahlich et al., 2009). 
Second, as demonstrated by its interaction with RNAPII and TFIID, EWS has roles in 
transcription (Bertolotti et al., 1996; Bertolotti et al., 1998), a major source of R-loops. Third, a 
role for EWS has also been proposed in RNA splicing (Michaud and Reed, 1993; Paronetto et 
al., 2011), and there is indirect evidence that defective splicing promotes R-loop accumulation (Li 
and Manley, 2005a; Li and Manley, 2005b; Paulsen et al., 2009). 
7.1. EWS is recruited to the nucleolus after nucleolar stress 
As previously published (Rossow and Janknecht, 2001), immunostaining of wild-type cultured 
MEF showed a widespread nuclear localization of EWS (Figure 28A). As already mentioned, 
TopoI relieves torsional stress during transcription. Importantly, R-loops forming at the rDNA 
region in yeast cells are significantly increased in top1Δ mutant strains (El Hage et al., 2010). 
Consistent with a role for EWS in R-loop metabolism, inhibition of TopoI by treatment with 
CPT promoted EWS nucleolar localization (Figure 28A). Recruitment to nucleoli was very fast, 
occurring within 10’ after CPT addition in 100% of the cells, and dispersal from the nucleolus 
 
Figure 28 
EWS protein is recruited to the nucleolus after nucleolar RS. (A) R-loop levels are increased in nucleoli after CPT treatment. Plot shows 
HTM-mediated quantification of nuclear S9.6 signal in untreated or 10nM CPT-treated wild-type MEF. (B) Representative images from A. 
(C) EWS is recruited to the nucleolus after CPT treatment. Immunofluorescent co-staining of EWS and Fibrillarin in wild-type MEF before 
and after treatment with CPT 10µM for 20’. (D) Wild-type MEF were treated with CPT 10µM for different times and immunostained as in 
C. Percentage of cells with nucleolar localization of EWS was quantified for each timepoint. 
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happened progressively within the following 8 hours (Figure 28B). Based on this evidence, we 
wondered whether the cause of RS in EWS-deficient and EWS/FLI1-expressing cells was an 
accumulation of R-loops. 
7.2. Ewsr1GT/GT and EWS/FLI1-expressing cells have increased 
R-loops 
We measured total levels of R-loops in Ewsr1GT/GT and EWS/FLI1-expressing MEF by HTM-
mediated quantification of S9.6 signal. Strikingly, both Ewsr1GT/GT and EWS/FLI1-expressing 
MEF had increased R-loops compared to their corresponding counterparts (Figure 29A and B). 
Representative pictures of Ewsr1+/+ and Ewsr1GT/GT MEF are shown (Figure 29C). Next we asked 
about R-loop levels at RNAPII-transcribed genes. To explore this, we collaborated with the lab 
of Andrés Aguilera, with renowned knowledge and expertise in R-loop biology. In collaboration 
with María García Rubio we performed DRIP-qPCR to assess R-loop levels at particular sites. 
The Airn gene was defined as an R-loop hotspot site in mouse cells (Ginno et al., 2012). 
Measurement at two different regions of the gene (Airn1 and Airn2) showed that both 
Ewsr1GT/GT and EWS/FLI1-expressing MEF had significantly increased R-loop levels, which 
were abolished upon RNAseH sample treatment as expected (Figure 29D and E). Next, we 
wondered whether ES cell lines had increased R-loops as well. For this we assessed R-loop levels 
in APOE, RPL13A and ERG1, described as R-loop hotspot sites in human cells (Ginno et al., 
2012). Strikingly, R-loops were increased in all ES cell lines compared to a control cell line 
(Figure 29F). Hence, increased R-loop levels appear to be the cause of RS in EWS-depleted and 
EWS/FLI1-expressing cells, as well as in ES cell lines. 
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Figure 29 
EWS-depleted, EWS/FLI1-expressing and ES cell lines accumulate R-loops in the nucleolus and in RNAPII-expressed genes. (A) 
Ewsr1+/+ and Ewsr1GT/GT MEF were stained with S9.6 and nuclear signal was quantified by HTM. (B) WT and EWS/FLI1-expressing MEF 
were stained with S9.6 and nuclear signal was quantified by HTM. (C), representative pictures of (A). (D, E and F) Quantification of R-
loops at RNAPII-transcribed genes by DRIP-qRT-PCR in Ewsr1+/+ and Ewsr1GT/GT MEF (D), WT and EWS/FLI1-expressing MEF (E), and 
ES cell lines and control cell lines (F). Extracted DNA was mock-digested or digested with RNAseH1 and immunoprecipitation with S9.6 
was performed. qRT-PCR on the indicated genes was used as a measure of R-loop acumulation. Data in D, E and F were produced in a 
collaboration with Andrés Aguilera and María García Rubio. All data are representative of at least 3 independent experiments. 
 
  RESULTS 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
77 
7.3. R-loops persist into mitosiss 
rDNA genes are organized in tandem repeats at the so-called nucleolar organizer regions (NOR), 
and account for around 80% of total RNA synthesis in eukaryotic cells. The repetitive and highly 
transcribed rDNA has a propensity to breakage (Butler, 1992; Huang et al., 2012). Provided that 
R-loops accumulate constitutively at NOR regions (Figure 27C), we inferred that R-loops might 
be the cause of such instability. In this regard, we wondered whether R-loops persist into 
mitosis, where chromosomal segregation of underreplicated DNA frequently results in 
chromosomal breakage. In mice and humans, NORs are localized at subcentromeric regions 
(Babu and Verma, 1985; Goodpasture and Bloom, 1975) in a variable number of chromosomes, 
depending on the species, and ranging from 5 to 8 (Heliot et al., 1997). NORs can be specifically 
identified on metaphases by either in situ hybridization with an rDNA probe or by 
immunolabeling with NOR-specific proteins such as RNAPI or UBF, which remain associated 
to rDNA genes during mitosis (Roussel et al., 1996; Weisenberger and Scheer, 1995). We 
prepared metaphase spreads of wild-type MEF and U2OS cells and stained them with S9.6. 
Surprisingly, all metaphases systematically presented an S9.6 staining pattern matching that of 
NOR regions. S9.6 signals were subcentromeric, as evidenced by their localization below the 
 
Figure 30 
R-loops are detected  at NOR regions in metaphasic chromosomes. (A) A wild-type MEF metaphase spread immunostained with S9.6 
antibody. (B) U2OS metaphase spreads with Immuno-FISH for s9.6 staining and a hybridization probe for NOR regions. The two signals 
colocalize at subcentromeric regions.   
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high density regions that correspond to centromeres (Figure 30A). A total of 6 to 8 
chromosomes within a metaphase presented an S9.6 signal. Immuno-FISH with a NOR-specific 
probe demonstrated S9.6 colocalization to NOR regions (Figure 30B). This novel finding opens 
new interrogants regarding the persistence of R-loops into mitosis, which, to our knowledge, has 
not been described to date. For the scope of this work, S9.6 antibody proved to be a bona fide 
marker of NOR regions. 
7.4. Ewsr1GT/GT MEF have increased genomic instability at 
NOR regions 
Next we asked about the consequences of having increased R-loops in EWS-deficient cells. In 
section 6 we detected RS-derived genomic instability in Ewsr1GT/GT MEF (Figure 24), consistent 
with several works reporting genomic instability as a consequence of RS. We now speculated that 
R-loop-derived RS might have a preferential impact on genomic instability at highly transcribed 
regions, such as NORs. To assess this we focused our metaphase breakage analysis on NOR 
regions. We stained Ewsr1+/+ and Ewsr1GT/GT MEF metaphase spreads with S9.6 and a telomeric 
probe (Figure 31A) and quantified the fraction of breaks and aberrations occurring specifically at 
NOR regions. Strikingly, the ratio of NOR-specific breaks over total breaks was increased in 
Ewsr1GT/GT cells (Figure 31B). Examples of NOR-specific chromosomal breaks (Figure 31A, 
white arrows) and chromatid breaks (Figure 31C) are shown. Of note, the mean ratios of NOR-
specific breaks range from 5% to 16%. Therefore, the increased breakage at NOR regions 
cannot account for global breakage differences between Ewsr1+/+ and Ewsr1GT/GT cells (Figure 
24). Altogether, data indicates that EWS-deficient cells have an increased fragility both globally 
throughout the genome and specifically at NOR regions. 
We repeated the breakage analyses on EWS/FLI1-expressing cells. However, these did not 
follow the tendency of Ewsr1GT/GT cells; instead, instability was rather decreased upon expression 
of EWS/FLI1. A parsimonious explanation is that the decrease in the proliferation rate upon 
expression of EWS/FLI1 (Figure 19D) prevents replication-driven genomic instability. Because 
RS-derived fragility is dependent on replication, a reduced replication rate might mask fragility at 
EWS/FLI1-expressing cells.   
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7.5. Biogenesis of rRNA is unaltered in Ewsr1GT/GT and 
EWS/FLI1-expressing cells 
Next we wondered about the causes of R-loop accumulation in EWS-deficient cells. Since EWS 
had been previously linked to RNA splicing and processing (Paronetto, 2013; Paronetto et al., 
2011), and because R-loops indeed accumulate preferentially at nucleoli, we speculated whether 
R-loop accumulation in Ewsr1GT/GT and EWS/FLI1-expressing MEF might be the result of an 
 
Figure 31 
Genome instability is specifically increased at NOR regions in Ewsr1GT/GT MEF. (A) Representative pictures of Ewsr1+/+ and Ewsr1GT/GT 
MEF metaphase spreads. White arrows point the two chromosome fragments resulting from a chomosomal break that occurred at a NOR 
region. (B) Quantification of chromosomal aberrations occuring at NOR regions relative to total aberrations in Ewsr1+/+ and Ewsr1GT/GT 
MEF. (C) Examples of chromatid breaks occurring at NOR regions. Data B are representative of 3 independent experiments.  
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altered rRNA biogenesis. An aberrant accumulation of abortive rRNA intermediates might clog 
up the processing of RNA and subsequently facilitate R-loop accumulation. 
A schematic representation of the rDNA complete repeating unit is depicted in Figure 32A. The 
transcribed 47S rRNA precursor is subjected to successive steps of cleavage giving rise to a 
variety of intermediate substrates and ultimately to the mature rRNA molecules 18S, 5.8S and 
28S (Figure 32B). To assess rRNA biogenesis we used a set of primers mapping several regions 
of the 47S precursor (Figure 32C, scheme below the graph), including the 5' ETS as a measure of 
47S precursor; 18S, 5.8S and 28S as a measure of mature rRNAs; and junctions between mature 
 
Figure 32 
Biogenesis of rRNA is not affected in cells lacking EWS. (A) Schematic representation of the rDNA repetitive sequence and 47S repeating 
unit. NTS, non-transcribed sequence; ETS, external transcribed sequence; ITS, internal transcribed sequence. (B) Intermediate products 
of processing of the 47S precursor. Depending on the cleavage order at the different cleavage sites, different intermediates are generated 
that ultimately give rise to mature 18S, 5.8Sand 28S. Panel B adapted from (Wang Anikin and Pestov 2014). (C) Normalized fold change 
expression in Ewsr1GT/GT compared to Ewsr1+/+, relativized to expression of the 47S precursor. (D and E) Northern blot of total RNA 
extracts of untreated or 3h 10µM CPT-treated, Ewsr1+/+ and Ewsr1GT/GT MEF with probes hybridizing to ITS1 (D; probe ITS1, labeled in 
red in B) and to ITS2 (E; probe ITS2, labeled in red in B). (F) Northern blot of total RNA extracts of Ewsr1+/+ and Ewsr1GT/GT embryonic 
livers with probe ITS1. 
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rRNA sequences and contiguous ITSs to quantify the diverse intermediate products (Kwon et 
al., 2014). We performed quantitative RT-PCR and analyzed the relative abundances of mature 
rRNAs and intermediates with respect to 47S precursor (Figure 32C). However, we considered 
our data inconclusive because of a high variability across samples and experiment repetitions; in 
any case, we did not observe an overall defect across the distinct independent pairs of cells 
tested. 
We decided to use a different approach to query the rRNA biogenesis function. Northern 
blotting of total RNA extracts enables the detection of distinct intermediates of rRNA 
biogenesis (O'Donohue et al., 2010; Wang et al., 2014). We used a probe to the ITS1, which 
hybridizes to all 18S precursors, and another one to ITS2, which hybridizes to all 5.8S/28S 
precursors (red labels at Figure 32B). No differences in rRNA intermediates were observed 
between Ewsr1+/+ and Ewsr1GT/GT cells with the ITS1 or the ITS2 probe, and challenging cells 
with CPT did not result in any differences either (Figure 32D and E). Based on the high γH2AX 
rates observed at E18.5 embryonic livers (Figure 22E), we also tested embryonic liver RNA 
extracts, but again no significant differences were observed (Figure 32F). Hence, analysis of 
rRNA biogenesis, both by quantitative RT-PCR and by northern blotting, failed to detect 
alterations in rRNA biogenesis, suggesting that other causes could be responsible for R-loop 
accumulation in EWS-defective cells.  
7.6. RNA nuclear export is impaired in Ewsr1GT/GT and 
EWS/FLI1-expressing cells 
EWS is a substrate of PRMT1 (Araya et al., 2005), which also regulates CHTOP (Chromatin 
Target Of PRMT1). CHTOP is a component of the THO/TREX complex, with a role in 
mRNA nuclear export. Importantly, as mentioned at the introduction, mutations in the 
THO/TREX complex are responsible for R-loop accumulation and genome instability 
(Dominguez-Sanchez et al., 2011; Gomez-Gonzalez et al., 2011; Huertas and Aguilera, 2003). We 
speculated that EWS role in limiting R-loop accumulation might relate to nuclear export of 
RNA. Vanesa Lafarga at our lab contributed importantly to address this. To determine RNA 
export rates, we pulsed Ewsr1+/+ and Ewsr1GT/GT MEF with EU (a ribonucleotide analog) to label 
nascent RNAs, and released them in fresh media for increasing time lapses (Figure 33A). 
Expectedly, labeled RNA molecules (particularly enriched at nucleoli) progressively migrated 
from the nucleus to the cytoplasm as evidenced by a nuclear signal decrease over time and a 
concomitant signal increase at the cytoplasm. Given that RNA degradation occurs only at the 
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cytoplasm and not at the nucleus, the decrease in nuclear EU signal can be interpreted as a 
surrogate indicator of RNA export. Strikingly, nuclear signal decrease was retarded in Ewsr1GT/GT 
cells, indicating an impaired export of newly synthesized RNA molecules (Figure 33B). 
Quantification of cells categorized as “EU-retaining” (black double-ended arrow in B) is plotted 
along time (Figure 33C). We repeated the assay for WT and EWS/FLI1-expressing MEF and we 
found a similar export retardation in EWS/FLI1-expressing MEF (Figure 33D). Representative 
pictures of Ewsr1+/+ and Ewsr1GT/GT MEF at timepoints 0 and 240min after release are shown 
(Figure 33E). These results suggest that EWS might contribute to prevent R-loop accumulation 
by promoting RNA nuclear export, and again point to a putative dominant-negative effect of 
EWS/FLI1 over EWS. 
Altogether, in section 7 we have demonstrated an R-loop accumulation in EWS-depleted and 
EWS/FLI1-expressing cells which recalls the R-loop accumulation detected in ES cell lines. We 
observed a concomitant retardation of RNA export, which might be responsible for R-loop 
accumulation. Increased genomic instability at NOR regions in EWS-depleted cells is a probable 
 
Figure 33 
RNA transcripts are retained in the nucleus in EWS-depleted or EWS/FLI1-expressing cells. (A) Experimental pipeline is depicted. 
Cultured cells were pulsed with EU for 1.5h and subsequently washed and released in fresh media for different times. Cells were fixed and 
processed for HTM-mediated quantification of EU nuclear signal. (B) HTM analysis of nuclear retention of EU-labeled transcripts in 
Ewsr1+/+ and Ewsr1GT/GT MEF. A threshold (grey horizontal line) was set to define subpopulations of EU-high nuclei. (C) Graphic 
representation of subpopulations of Ewsr1+/+ and Ewsr1GT/GT EU-high nuclei in B. (D) Graphic representation of percentages of WT and 
EWS/FLI1-expressing EU-high nuclei. (E) Representative pictures of EU-labeled nuclei at timepoints 0 and 240min from experiment B. All 
experiments were performed by Vanesa Lafarga. Two independent MEF pairs were assayed in each experiment. 
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consequence of R-loops. These data suggests that R-loop accumulation is the cause of RS and 
genomic instability in Ewing sarcomas. In addition, parallel responses of EWS/FLI1-expressing 
cells and EWS-depleted cells suggest that EWS/FLI1 has a dominant-negative effect over EWS.  
Regarding the clinical treatment of Ewing sarcoma, the identification of high RS levels in ES 
cells, as well as in EWS/FLI1-expressing and EWS-deficient cells, provides a rationale for the 
use of ATR inhibitors as a chemoterapeutic agent to treat Ewing sarcomas. Furthermore, we 
have proved the in vivo efficacy of this approach. Additionally, the findings described in this work 
provide a mechanistic explanation for the efficacy of currently used chemotherapies. CPT 
derivatives topotecan and irinotecan are used in the clinics and continue to be explored for 
improving the treatment of relapsed Ewing sarcoma (Kurucu et al., 2015), but the molecular 
basis of their toxicity to Ewing sarcoma remained unknown. Our study shows that the inability 
of EWS-deficient cells to limit R-loop accumulation might be responsible for sensitization to an 
agent that increases R-loop levels, such as CPT. Together, these findings might hopefully have a 
translation into the clinics and thus contribute to improve the prognosis of this pediatric cancer. 
8. Consequences of Ewsr1 deletion in adult mice 
We next wondered whether RS is just a byproduct of the pathology of Ewing sarcomas - a 
feature that we indeed can exploit as an Achilles’ heel to treat this cancer -, or it is rather an early 
event that constitutes a driving force for malignant transformation. Assuming the latter, RS 
derived from EWS deficiency might actively contribute to the development of Ewing sarcomas. 
Whereas EWS/FLI1oncogenic activity has been proven in a number of EWS/FLI1 transgenic 
mouse models (Ordonez et al., 2009), we wanted to assess the contribution of EWS to tumor 
suppression. On the other hand, as a proof of concept we were interested in exploring whether 
R-loop-driven genomic instability can fuel cancer, which has not been shown. 
As shown in section 5 (Figure 22), constitutive deletion of Ewsr1 is embryonic lethal. Therefore, 
to explore the impact of Ewsr1 deletion in adult mice we used the conditional knockout version 
of our Ewsr1 allele. We obtained that by breeding FLP transgenic mice into mice bearing the 
Ewsr1GT allele (Figure 21). FLP-mediated recombination of the FRT sites converted the gene-
trapped allele into a conditional allele (Ewsr1lox) and restored gene activity.  
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8.1.    Exploring a tumorigenic effect of Ewsr1 deletion 
Bmi1 is a known player in the self-renewal of adult stem cells (Lessard and Sauvageau, 2003; 
Leung et al., 2004; Molofsky et al., 2003). A CRE recombinase expressed under the control of 
the Bmi1 promoter (Bmi1-CREERT2) proved to be a valuable tool for the development of ESFT-
like tumors in a mouse model for conditional expression of EWS/ATF1 fusion protein 
(Straessler et al., 2013). Based on this we bred mice bearing Bmi1-CREERT2 to mice bearing the 
Ewsr1lox allele and we generated a cohort of Ewsr1+/+ :: Bmi1-CreERT2 and Ewsr1lox/lox :: Bmi1-
CreERT2 mice in mixed litters. Mice were put on OHT-rich diet from the fourth week of age to 
induce CRE-mediated excision. However, at the moment of publication of the present work, 
Ewsr1lox/lox :: Bmi1-CreERT2 (Ewsr1
Δ/Δ, hereafter) have not shown an increased tumoral incidence, 
being 30 to 40 weeks old. In spite of this result, we cannot discard that EWS has a tumor 
suppressive role. Further study is needed in this regard; codepletion of p53 as a key tumor 
suppressor, or expression of known oncogenes such as Eµ-Myc, might preferentially favor 
tumorigenesis in a context of genomic instability such as in Ewsr1
Δ/Δ mice. On the other hand, 
the Bmi1-expressing cell population might not be the right target to test the tumorigenic 
potential of Ewsr1 deletion; in this sense, the use of a more ubiquitously expressed CRE 
recombinase would help highlight susceptibility to tumorigenesis in any tissue. There are ongoing 
experiments in these two directions that might help us address whether EWS has a tumor 
protective contribution, and whether R-loop-driven genomic instability can fuel tumorigenesis. 
8.2. Ewsr1Δ/Δ mice develop an ALS-like disease 
In contrast to tumorigenesis, Ewsr1
Δ/Δ mice developed motor problems. As mice aged, Ewsr1
Δ/Δ 
animals presented scoliosis with a variable degree of incidence and intensity (Figure 34A). Unlike 
kyphosis, which appears in mice during normal ageing, scoliosis is not a common feature in aged 
mice. We speculated that the underlying cause might relate to motor problems at the 
neuromuscular level. Postural compensation of asymmetrical motor problems on the limbs 
might at the long term result in spinal cord deformation and scoliosis. To investigate motor 
capacity in the mice, we studied hindlimb extension performance. The hindlimb extension reflex 
is the reflex by which mice extend their hindlimbs immediately upon being lifted by the tail. 
Hindlimb clasping and failure to extend upon lifting is indicative of abnormal motor function. 
We classified mice in three categories based on their extension capacity (full, partial or null; 
Figure 34B), and we also assessed symmetrical or asymmetrical performance. These parameters 
are commonly used for neurological scoring in mouse models of neurodegeneration (Acevedo-
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Arozena et al., 2011) (Leitner et al., 2009). Ewsr1
Δ/Δ mice showed a decreased capacity of 
extension compared to Ewsr1+/+ mice (Figure 34C), as well as an increased asymmetry during 
performance (Figure 34D). Analysis of subpopulations revealed interesting data: extension 
defects aggravated upon ageing, consistent with a neurodegenerative defect, and were more 
pronounced in males than in females (Figure 34C). All of the above are reminiscent of 
amyotrophic lateral sclerosis (ALS), which is age-associated and has a greater incidence in males. 
Assymetry in Ewsr1
Δ/Δ mice was also reminiscent of ALS, as motor defects in ALS typically 
initiate locally at one side of the body and later extend to the rest, and this was also aggravated in 
males (Figure 34D). 
 
Figure 34 
EWS-depleted mice have a reduced hind limb extension capacity and display an increased asymmetry during extension. (A) 53-week-old 
Ewsr1+/+ and Ewsr1Δ/Δ littermates. Ewsr1Δ/Δ mouse presents scoliosis. Yellow dashed lines indicate spinal cord path. (B) Scoring of 
extension capacity during hind limb extension reflex. (C) Distributions of extension capacity groups within Ewsr1+/+ and Ewsr1Δ/Δ mice. 
Panels correspond to general population, females, males, young (<=30 week-old) animals and aged (>30 week-old) animals, respectively. 
(D) Distributions of animals performing extension symmetrically or asymmetrically. Panels correspond to general population, females and 
males. Only animals with full or partial extension capacity were evaluated for symmetry/asymmetry. Numbers of animals in each group are 
indicated on top of the corresponding columns. 
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ALS (OMIM #105400) is a neurodegenerative disorder characterized by the death of motor 
neurons (MN) in the brain and spinal cord. It usually begins with asymmetric atrophy of limb 
muscles in mid-life, and muscular function is progressively impaired leading to paralysis and 
death (Boillee et al., 2006; Pasinelli and Brown, 2006). Up to 10% of ALS cases are familial 
(fALS) (Dion et al., 2009), usually autosomal dominant. Defects in several genes have been 
reported to cause ALS, SOD1 being the most prevalent cause in fALS (Rosen et al., 1993). 
Mutations in FUS and Senataxin are also causative of fALS (Chen et al., 2004; Kwiatkowski et 
al., 2009) and, intriguingly, sequentiation of the EWSR1 gene in 817 individuals diagnosed with 
ALS revealed deleterious mutations at the RNA binding domains of EWS in 2 independent 
patients.  
Several transgenic mouse models of SOD1 have been developed that recapitulate the disease 
(Bruijn et al., 1997; Gurney et al., 1994; Jonsson et al., 2004; Jonsson et al., 2006; Wong et al., 
1995). A hallmark of ALS is the loss of MNs, a feature that is shared in ALS mouse models 
(Acevedo-Arozena et al., 2011; Pasinelli and Brown, 2006), and vacuolization at the neuronal 
bodies is also observed in both ALS patients and mice (Riancho et al., 2014; Vinsant et al., 2013; 
Wong et al., 1995). Based on this we explored the MN population at the spinal cords of aged 
Ewsr1+/+ and Ewsr1
Δ/Δ mice. Strikingly, MN counts were decreased in Ewsr1
Δ/Δ mice (Figure 35A 
and B), and they presented a severe vacuolization as assessed by Cresyl violet staining (Figure 
35C).  
Whether the R-loop-limiting role of EWS is related to the ALS-like phenotype observed in 
Ewsr1
Δ/Δ mice, and whether R-loops do actually accumulate in motor neurons remain open 
questions that need to be addressed. Still, these preliminary results suggest that EWS has a 
neuroprotective role, and that EWS deficiency in the adult Bmi1-positive stem cell compartment 
can trigger a progressive ALS in mice. 
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Figure 35 
Motor neuron counts are reduced in aged Ewsr1
Δ/Δ mice and present vacuolization at neuronal bodies. (A) Transversal sections of 
thoracic spinal cords of 53-week-old Ewsr1+/+ and Ewsr1
Δ/Δ mice. Insets show ventral horns (area delimited by dashed line) where motor 
neurons are identified by shape and size. Arrows point to some motor neurons. Scale bars, 100 µM (B) Quantification of motor neuron 
counts in aged Ewsr1+/+ and Ewsr1
Δ/Δ mice. n=2 mice per genotype. At least 3 ventral horns per mouse were analyzed. (C) 
Representative pictures of motor neurons. Scale bar, 16 µM. 
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DISCUSSION 
 
PART I: Modest impact of FBH1 deficiency in mammals 
 
The first objective of this PhD was to evaluate the in vivo contribution of FBH1 to maintenance 
of genome integrity. In this study we have developed a mouse strain for deletion of Fbh1. We 
have observed a moderate impact of Fbh1 deletion on mouse weight and on RS-derived 
signaling, but embryonary development, viability and fertility were unaltered, and we failed to 
detect any other deficiency on the previously described roles of this helicase.  
Consistent with other studies (Fugger et al., 2009) we detected attenuated signaling after RS at 
the cellular level, including a mild decrease in RPA phosphorylation and in γH2AX. However, 
we were unable to detect an altered cellular response, either in damage repair, cell cycle 
arrest/regulation or cellular viability (Figure 11). According to recent work (Fugger et al., 2013; 
Jeong et al., 2013b), FBH1 mediates apoptosis in the presence of excessive RS, and decreased 
signaling in FBH1-depleted cells results in deficient activation of pro-apoptotic pathways. 
Nonetheless, cell cycle profiles of Fbh1GT/GT cells revealed no increased survival rates, either in 
untreated cells or after inducing RS with HU or ATRi. One possible explanation is that apoptosis 
is only abrogated below a certain threshold of pro-apoptotic signaling, and Fbh1 deletion reduces 
RS-derived signalling to a level that does not reach this threshold. Therefore, reduced signaling is 
observed but abrogation of apoptosis is not. Whether or not this is the case, remains an 
unanswered question. Remarkably, we bred the Fbh1GT allele into ATRS/S mice, which suffer 
from RS and undergo cellular apoptosis during embryo development. Importantly, Fbh1 deletion 
did not rescue any of the ATRS/S phenotypes; on the contrary, it further aggravated it (Figure 12). 
Therefore, both at the cellular and at the organism level, our results do not support the 
aforementioned model, by which FBH1 would promote apoptosis in cells accumulating 
excessive RS. We do not discard this model either; in ATRS/S mice, the absence of an 
orchestrated apoptosis in stressed cells upon Fbh1 deletion might have effects that are even more 
detrimental at the organism level, and thus lead to a further aggravation of the ATRS/S 
phenotype, although these data are at this point preliminary and the hypothesis remains to be 
strengthened. Regardless of the precise function of FBH1, the proposed pro-apoptotic role 
suggests a tumor suppressor function, by which cells with genomic instability derived from 
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excessive RS are eliminated from the organism to prevent malignant transformation. This is 
supported by mutations or deletions detected at the FBH1 gene in human melanoma cell lines 
(Jeong et al., 2013a). However, our colony of Fbh1GT/GT mice did not present an increased 
incidence of tumors, and thus does not support this hypothesis. Perhaps mutations linked to 
development of melanoma, such as loss of PTEN or expression of BRAFV600E (Mehnert and 
Kluger, 2012), might increase the susceptibility of FBH1-deficient animals to develop cancer. 
The use of mouse models of melanoma might help address this issue at the organism level. 
Mechanistically, several in vitro and cellular studies have shown that FBH1 negatively regulates 
the Rad51 nucleofilament by disrupting it through its helicase-translocase activity and by 
ubiquitylating it to prevent re-recruitment (Chu et al., 2015; Simandlova et al., 2013; Tsutsui et 
al., 2014). In these works, FBH1 depletion in cellular models resulted in retention of Rad51 in 
the chromatin fraction after sub cellular fractionation. However, in the present study, Fbh1+/+ 
and Fbh1GT/GT cells did not show any difference in Rad51 binding to chromatin, either in basal 
conditions or after MMC treatment, and total Rad51 levels were unaltered (Figure 13). 
Consistently, we did not observe any phenotypes derived of excessive or unscheduled HR in 
Fbh1GT/GT cells, such as breakage or aberrations in metaphase chromosomes. This reinforces the 
idea that higher eukaryotes have evolved redundant mechanisms for HR regulation, making 
FBH1 dispensable for RS-derived HR (Fugger et al., 2009; Kohzaki et al., 2007).  
FBH1 was proposed to be a functional homolog of the yeast canonical anti-recombinase Srs2. In 
this regard, Simandlova and colleagues found that mutant FBH1 cells were resistant to PARP1 
inhibition. This argues in favor of an anti-recombinase role for FBH1, as deletion of pro-
recombination factors such as BRCA1 generate hypersensitivity to PARP1 inhibition (Farmer et 
al., 2005). BRCA1 mutant mice have a strong phenotype with embryonic lethality and impaired 
HR in cell cultures. We aimed at obtaining genetic proof of the anti-recombinase activity of 
FBH1 by deleting Fbh1 in BRCA1 mutant mice. The reasoning was that removing a negative 
regulator of HR might restore HR to some extent in those animals. However, deletinon of Fbh1 
in did not show any rescue of the BRCA1 mutant phenotype, indicating that FBH1 loss does not 
compensate for a low-recombinant phenotype (Figure 14). In line with this, Fbh1 deletion did 
not have an impact on the efficiency of class-switch recombination, a physiological process in B 
cells that invokes NHEJ as opposed to HR (Bunting et al., 2010). Taken together, we could not 
demonstrate an anti-recombinase activity of FBH1 in vivo. Again, this might reflect a pathway 
redundancy existing in higher eukariotes. 
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To summarize, we found that FBH1 has a moderate role in signaling RS, although we could not 
detect any effects of Fbh1 deletion in terms of genomic instability or tumorigenesis. An impact of 
FBH1 on regulation of HR was not detected, either at the cellular level or in animals with a 
genetic background involving limited HR. Whereas putative homolog Srs2 in yeasts limits HR 
and is critical for resistance to DNA damaging agents, it is possible that higher eukaryotes have 
evolved redundant mechanisms for regulating HR, so that in mammals FBH1 is dispensable for 
a proficient HR. In this regard several works propose RTEL1 helicase as another functional 
homolog of yeast anti-recombinase Srs2 (Barber et al., 2008). One possibility is that several 
proteins, including FBH1 and RTEL1, contribute to regulating HR and are sufficient to fulfill 
their function in the absence of functional partners. Alternatively, differences between the 
present model and previous approaches might explain the opposing observations. Many studies 
were performed with RNA interference of Fbh1 which promotes depletion of the protein 
immediately before observation; instead, constitutive genetic deletion of Fbh1 in mice might let 
the organism re-wire alternative pathways to compensate for the lack of FBH1. In this scenario, 
we might have underestimated the actual roles of FBH1 at the organism level; in any case, these 
roles are most probably non-essential and/or compensable. 
The mouse strain described in this work might serve to further study genetic interactions 
between FBH1 and players of the HR and the RS-response pathways, and as a genetic model of 
FBH1 deficiency to unravel the molecular mechanisms of this elusive helicase. 
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PART II: New insights into Ewing sarcoma and EWS function 
 
1. Exploiting tumor-associated RS for the treatment of Ewing 
sarcoma  
RS is a relevant source of DNA damage and genomic instability (Lecona and Fernandez-
Capetillo, 2014). Interestingly, Ewing sarcoma has a high rate of genomic rearrangements 
(Ferreira et al., 2008; Ohali et al., 2004) but is among the tumor types with lowest point mutation 
frequency (Alexandrov et al., 2013), which together is reminiscent of RS. In the present work we 
have detected increased levels of RS in Ewing sarcoma (Figure 15 and Figure 16). In our lab we 
previously showed that tumors with increased RS levels, such as Eu-myc lymphoma, H-Ras 
fibrosarcoma and MLL-ENL AML, are especially dependent on ATR activity and can be 
selectively targeted by inhibiting ATR, which drives the rapidly growing tumoral cells to 
unrestrained cell cycle progression and mitotic catastrophe (Murga et al., 2011; Schoppy et al., 
2012). We have here shown that ES cells are hypersensitive to ATR inhibition (Figure 17), and 
that inhibiting ATR efficiently abrogates Ewing sarcoma xenograft growth (Figure 18). 
Remarkably, our ATRi is specifically toxic to ES cell lines at doses at which it is not toxic to 
control cell lines. In relation to other drugs, ATRi is almost 100-fold more toxic to ES cells than 
Olaparib and at least 104-fold more toxic tan TMZ (Figure 17C), two drugs that are being tested 
in combination in clinical trials as an alternative to current chemoterapeutics for the treatment of 
Ewing sarcomas (NCT01858168; https://clinicaltrials.gov/ct2/show/NCT01858168).  
2. Understanding Ewing sarcoma: R-loops are responsible for RS 
Multiple processes can contribute to increase RS in proliferating cells; one is the aberrant 
accumulation or persistency of R-loops. In this work we have determined an accumulation of R-
loops in ES cell lines and in EWS-defective cells (Figure 29), revealing R-loops as the source of 
RS in this particular tumor type. Several links have been suggested between R-loops and cancer 
(reviewed in (Groh and Gromak, 2014); most remarkably, BRCA2 (a tumor suppressor that is 
frequently mutated in breast cancer) was found to be required for preventing R-loop 
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accumulation (Bhatia et al., 2014). Nonetheless, for the first time we are reporting the distinctive 
presence of R-loops in a particular type of cancer. 
Our findings in this work provide a mechanistic explanation for the hypersensitivity of Ewing 
sarcomas to TopoI inhibitors, which remained not understood to date. CPT inhibits TopoI, an 
enzyme that relieves torsional stress during transcription, and mutation of top1 (yeast TopoI 
homolog) results in R-loop accumulation (El Hage et al., 2010). Work by Vanesa Lafarga at our 
lab has demonstrated that a deficiency in R-loop-suppressing mechanisms sensitizes cells to CPT 
and ATRi (unpublished data). We have detected a high sensitivity of EWS-deficient cells to CPT 
and, significantly, TopoI inhibitors topotecan and irinotecan are being explored for 
chemotherapy of Ewing sarcoma with promising results (Kurucu et al., 2015), although the basis 
of this sensitivity remained elusive. We here show that sensitivity of Ewing sarcomas to TopoI 
inhibitors is based on their inability to limit R-loop accumulation.  
Whereas CPT generates a high burden of R-loop-derived RS, ATRi has an essentially different 
effect; it prevents a response to RS, thus aggravating its accumulation and impeding cell cycle 
checkpoint activation and arrest. Under these circumstances RS is extremely toxic, as cells have 
no emergency stop to prevent premature entry into mitosis. Under-replicated DNA causes 
segregation defects that lead cells to mitotic catastrophe. Based on this we suggest ATR 
inhibition as an alternative strategy to treat Ewing sarcomas, and we propose a combination of 
TopoI inhibitors with ATRi to induce RS-based synthetic lethality in Ewing sarcoma tumoral 
cells (Figure 36). 
Of note, in regards to RS, we base our conclusions on the levels and staining pattern of γH2AX 
 
Figure 36 
A synthetic lethal approach to target Ewing sarcomas based on the molecular mechanisms of this particular cancer type. Ewing sarcomas 
suffer from R-loop-derived RS. CPT or derivatives increase R-loop burden thereby impairing proper DNA replication. ATR inhibition 
pushes under-replicating cells to mitosis causing mitotic catastrophe and death. 
  DISCUSSION 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
95 
found in ES cell lines and EWS/FLI1-expressing cells, as well as on the hypersensitivity to RS-
inducing treatments. However, neither ES cell lines nor EWS/FLI1-expressing cells showed 
increased ssDNA or RPA foci (data not shown), which is a frequent outcome of fork stalling and 
a common readout of RS. For example, HU, a commonly used RS-inducing agent, promotes 
dNTP pool depletion leading to a blockade of the DNA polymerase and uncoupling of the 
helicase, which continues to unwind DNA ahead of the fork and generates extensive ssDNA 
threads (Byun et al., 2005). Nonetheless the absence of RPA foci at RS sites is not new. For 
instance, inter-strand crosslinks or DNA-protein adducts are physical barriers and can block 
replication fork progress whithout a concomitant helicase-polymerase uncoupling, and therefore 
do not lead to a significant ssDNA-RPA accumulation (Nam and Cortez, 2011). R-loops appear 
to be also physical obstacles to fork progression and may not allow uncoupling; therefore, 
uncoupling-derived ssDNA might not arise in this scenario, consistent with failure of ES cell 
lines EWS/FLI-expressing cells to show increased ssDNA in spite of RS evidence. In fact, this 
work highlights R-loops as an RPA-ssDNA-independent source of RS. It will be interesting to 
assess the means by which ATR is activated under these circumstances, which remains an open 
question. Furthermore, how common is R-loop-derived RS in physiological and pathological 
contexts, and what might be its contribution to pathogenesis needs to be addressed. 
3. Contributions of EWS deletion and EWS/FLI1 expression in 
tumorigenesis: molecular dissection 
Whereas the founding event leading to Ewing sarcoma is well established to be the translocation 
between EWSR1 and FLI1 genes, two direct consequences of the translocation can be identified: 
1) the production of an EWS/FLI1 fusion product, and 2) the interruption of one EWSR1 allele, 
and therefore loss of EWS activity. To dissect the contributions of each of these two conditions 
to R-loop accumulation and RS, we have benefited from a model for transgenic EWS/FLI1 
expression (Lin et al., 2008) and a model for deletion of EWS (described in this work) (Figure 
20).  
EWS/FLI1 ectopic expression in cells induces R-loops and RS, consistent with R-loops and RS 
detected in ES cell lines, indicating that R-loops in ES cell lines are a consequence of the 
translocation. Strikingly, EWS-deficient embryos show hallmarks of RS, and embryo-derived 
EWS-deficient cells also accumulate R-loops and RS, analogously to EWS/FLI1-expressing cells, 
and suffer from genomic instability. Furthermore, EWS-deficient cells are hypersensitive to CPT, 
consistent with the increased sensitivity of Ewing sarcomas to TopoI inhibitors. 
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The fact that EWS deletion phenocopies the defects in EWS/FLI1-expressing cells and in Ewing 
sarcomas, suggests that expression of EWS/FLI1 promotes a loss of function of EWS. In Ewing 
sarcomas one EWSR1 allele is involved in the founding translocation and, thus, expression of 
wild-type EWS from that allele is lost. However the other allele remains intact; in fact, EWS 
protein can be detected in ES cell lines in decreased amounts (Figure 16A). On the other hand, 
in the EWS/FLI1 model, the fusion protein is expressed from a transgene, and both Ewsr1 
alleles are intact. In both cases, loss of EWS activity might be explained through a putative 
dominant-negative effect of the fusion protein over EWS protein. Based on this, we propose 
that EWS works as an R-loop suppressor, and EWS/FLI1 has an indirect role in R-loop 
accumulation through inhibition of EWS activity (Figure 37). The parallel defects in both 
Ewsr1GT/GT cells and EWS/FLI1-expressing cells over R-loop accumulation, impaired RNA 
export and RS support the idea of an EWS loss-of-function common mechanism. Supporting 
this model, EWS and EWS/FLI1 were found to be co-interactors (Spahn et al., 2003). In any 
case, further research is needed in this regard. For example, it will be interesting to assess 
whether expression of EWS/FLI1 in EWS-deficient cells fails to further increase R-loops. 
 
 
Figure 37 
Molecular dissection of EWS and EWS/FLI1 
contributions to tumorigenesis. EWS/FLI1 is a 
reported oncogene that alters the bone 
transcriptional pattern and leads to tumorigenesis. 
Concomitant loss of EWS activity in carriers of the 
EWS/FLI1 translocation results in R-loop-driven RS 
and genomic instability. Whether this has an active 
contribution to tumorigenesis, remains an open 
question. 
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We further wondered about the role of R-loops in Ewing sarcoma. We have demonstrated an 
association of R-loops and Ewing sarcoma, but it remains unclear whether R-loop accumulation 
is merely a bystander or rather an active driver of tumorigenesis. Our findings do not discard that 
R-loop accumulation and subsequent RS are a mere byproduct of Ewing sarcoma biology, which 
indeed we can exploit to specifically target and kill tumoral cells through ATR inhibition or other 
strategies. Conversely, we can envision a scenario in which R-loop-driven RS has an active role in 
driving genomic instability and contributes to tumorigenesis. In other words, we speculate on the 
potential tumor suppressor role of EWS, independently of the proven oncogenic activity of the 
fusion protein EWS/FLI1, and we wonder about the tumorigenic potential of R-loop-driven RS 
(Figure 37). The genomic instability accumulating in EWS-deficient cells (Figure 31) supports 
this idea.  
However, deletion of EWS in the adult Bmi1-positive cell population has not lead to increased 
tumorigenesis. Because the cell of origin of Ewing sarcoma remains elusive (Lessnick and 
Ladanyi, 2012), the generation of appropriate mouse models is greatly hampered. In this sense, 
deletion of EWS in other cellular compartments on in the whole organism might highlight any 
tissue-specific susceptibility to tumorigenesis. On the other hand, concomitant deletion of a 
central tumor suppressor such as p53 might lower the threshold for malignant transformation 
and lead to a differential tumoral incidence in Ewsr1
Δ/Δ mice. Alternatively, our hypothesis might 
be wrong, and R-loop-derived RS might just be a bystander in Ewing sarcoma with no 
contribution to tumorigenesis. Ongoing experiments in the lab in these directions might shed 
light on these issues. 
4. EWS contribution to preventing neurodegeneration 
Besides the molecular determinants of Ewing sarcoma and speculations on EWS contribution to 
suppressing tumorigenesis, we have identified a neurodegenerative disorder in adult, EWS-
depleted mice that recapitulates several phenotypes of human ALS, including a decreased fitness 
in motor function and alterations in the MN population (Figure 34 and Figure 35). R-loops have 
been previously associated to ALS and other neurodegenerative disorders, and appear to be a 
central node linking a number of ALS-causing mutations (Salvi and Mekhail, 2015). Namely, 
mutations in SETX, a helicase that unwinds RNA:DNA hybrids and prevents R-loop 
accumulation, cause ALS (Chen et al., 2004). Actually in the lab we have observed that SETX 
knockdown leads to increased R-loops and sensitivity to TopoI inhibition (unpublished data). 
Mutations in ATXN2, with a described role in suppressing R-loops in yeast (Elden et al., 2010), 
  DISCUSSION 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
98 
are also linked to ALS. Hexanucleotide repeat expansion occurring at C9ORF72 gene mediates 
accumulation of R-loops and is responsible for ALS and FTD, a neurodegenerative disease with 
molecular similarities to ALS (Haeusler et al., 2014; Wang et al., 2015). Furthermore, mutations 
in FUS (a member of the FET family) and in TDP43 (a structurally related protein) are causative 
of ALS. Although R-loop involvement in these cases has not been established, mutations in FUS 
and TDP43 are responsible for nuclear protein depletion and engagement in cytoplasmic RNP 
aggregates such as stress granules (Alami et al., 2014; Kwiatkowski et al., 2009; Sreedharan et al., 
2008; Takanashi and Yamaguchi, 2014). Remarkably, wild-type EWS and TAF15 have also been 
reported to engage in such aggregates in tissue samples from FTD patients (Mackenzie and 
Neumann, 2012). Strikingly, deleterious mutations on EWSR1 were recently identified in two 
patients with ALS (Couthouis et al., 2012). For the first time we report EWS deficiency as 
responsible for a phenotype reminiscent of ALS. To our knowledge, EWS is unique in that it 
both limits R-loops and incorporates into aberrant cytoplasmic aggregates, two main molecular 
hallmarks of ALS. This model highlights the role of EWS in RNA metabolism and provides a 
link to neurodegenerative processes. Importantly, the EWS conditional knockout mouse 
described in this work might serve as a genetic model for ALS. 
5. A mechanism for EWS protein 
We were especially interested in understanding the mechanisms of EWS in R-loop biology and 
its implication in the pathogenesis of diseases as diverse as Ewing sarcoma and ALS. What is the 
molecular function of this elusive protein? Is one unique function of EWS responsible for 
preventing such diverse pathologies? Or are independent deficiencies whithin the protein 
responsible for each of the pathologies? Four lines of evidence help answer these questions.  
5.1. EWS is an R-loop suppressor 
In the present work we have identified a novel role for EWS in preventing R-loops and 
subsequent genomic instability. Consistently, EWS binds DNA G-quadruplexes (Takahama et 
al., 2011), structures that might help stabilize R-loops on the complementary strand (Hamperl 
and Cimprich, 2014). Furthermore, genomic instability, which is one consequence of R-loop  
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accumulation, has also been described in mice deficient for FET family partner FUS (Hicks et al., 
2000). EWS functional deficiency has an impact on the development of ALS, and possibly on  
cancer. The reduced RNA export rate observed in EWS-deficient cells (Figure 33) suggests that 
the R-loop-suppressive role of EWS is linked to the RNA export process.  
5.2.  EWS is recruited to particular genomic sites 
Under certain circumstances EWS is recruited to DSB. All three FET proteins, which share a 
high degree of homology, are recruited to laser microirradiation sites in a PARP1- and PAR-
dependent manner (Britton et al., 2014; Mastrocola et al., 2013; Rulten et al., 2014) suggesting a 
role in the response to DNA damage. FET proteins contain several RGG domains at their C-
terminal region (Figure 9). Whereas RGG domains were initially postulated to represent RNA 
binding motifs (Kiledjian and Dreyfuss, 1992), they might alternatively be responsible for 
recruitment to PAR chains synthesized at DSBs, based on PAR structural similarity to RNA. 
This would imply that the C-terminus is required for protein mobilization. Interestingly, the two 
EWS deleterious mutations detected in ALS patients are located at the RGG domains 
(Couthouis et al., 2012).  
EWS appears to have a distinct role at nucleoli. Immunofluorescent staining of U2OS cells 
showed nuclear staining with enhanced nucleolar localization in around 15% of cells (data not 
shown). Instead, in primary MEF, EWS is constitutively nuclear and excluded from nucleoli, and 
is recruited to nucleoli after UV irradiation (Paronetto et al., 2011) and after TopoI inhibition by 
CPT treatment (Figure 28). UV generates thymidin dimers and bulky adducts, whereas TopoI 
relieves torsional stress during transcription. Both conditions necessarily lead to transcription-
replication or pure transcriptional conflicts (Figure 27), and with a special incidence where 
 
 
Figure 38 
EWS is an R-loop suppressor. In an EWS-proficient context R-loops are efficiently 
removed and genome integrity is preserved. In an EWS-deficient context R-loops 
persist and accumulate, leading to RS and genomic instability. 
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transcription is more active: namely, at nucleoli. Whereas Paronetto and colleagues proposed that 
EWS was sequestered at the nucleoli as a strategy to prevent interruption of alternative splicing 
events in response to UV damage (Paronetto et al., 2011), we think EWS is has an active role in 
nucleoli in preventing R-loop accumulation. Consistent with this, EWS was found to be required 
for resistance to CPT in a genome wide sensitivity screen (O'Connell et al., 2010). Remarkably, 
BRCA1 and BARD1, which form a stable heterodimer required for regulation of RS-derived 
recombinatorial repair (Wu et al., 1996), were also top hits in that screen, and EWS has been 
found to interact with BARD1 (Spahn et al., 2002). This provides further evidence of the 
involvement of EWS in genome surveillance.  
5.3.  Self-aggregating properties of EWS 
FET proteins and other hnRNPs undergo self-aggregation in vitro (Kato et al., 2012). The 
process is mediated by a low complexity (LC) domain, which in EWS (and in FET proteins) is 
located at the N-terminus, within the SYGQ-rich region (Figure 39A). LC domains, present in 
numerous proteins, have been described to undergo a concentration-dependent and RNA-
dependent phase transition to a hydrogel-like state (Kato et al., 2012). Hydrogels are composed 
of uniformly polymerized amyloid-like fibers and can accommodate heterotypic polymerization 
in a dynamic manner. These observations might underlie a physiological organizing principle for 
the formation of membrane-less cellular structures. Both FET protein recruitment to laser 
microirradiation sites (Britton et al., 2014; Mastrocola et al., 2013; Rulten et al., 2014) and CPT-
induced recruitment of EWS to nucleoli might represent physiological responses involving self-
aggregation into hydrogels. Remarkably, the two EWSR1 independent mutations detected in 
ALS patients alter EWS localization in motor neurons, exhibiting enhanced aggregation 
propensity (Couthouis et al., 2012). Importantly, ALS-linked mutant variants of FUS and EWS 
showed RNA-dependent engagement in cytoplasmic aggregates (Bentmann et al., 2013; 
Couthouis et al., 2012) and tissue sections from FTD patients present cytosolic aggregates or 
stress granules containing all three FET proteins and other hnRNPs (Bosco et al., 2010; 
Kwiatkowski et al., 2009; Mackenzie and Neumann, 2012; Takanashi and Yamaguchi, 2014). We 
speculate that mutations that alter the nuclear localization and/or the determinants for self-
aggregation might result in enhanced/aberrant aggregation in the cytoplasm.  
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5.4.  A model for EWS mechanism 
Altogether, EWS mobilization to sites with genomic alterations (G-quadrulexes, DNA breaks, R-
loops) is dependent on its C-terminal nucleic acid binding domains, while polymerization into 
aggregates is mediated by its N-terminal LC sequences. EWS has been thoroughly described as 
being involved in transcription and RNA processing, and there has been increasing evidence of 
its role as a genome caretaker, although a connection between these two functions was missing. 
 
Figure 39 
A model for aggregation-mediated EWS activity. (A) The SYGQ repeats at the N-terminal region of EWS constitute low-complexity 
sequences, which are intrinsically unstructured. (B) LC domains undergo a concentration-dependent phase transition to a hydrogel-like 
state which is dependent on the presence of RNA. EWS polymerization promotes incorporation into hydrogels of other LC-containing 
proteins (purple and orange) which might exert functions at the site of polymerization, such as DNA damage repair or R-loop removal. 
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Based on our results and the literature briefly reviewed above, we propose a model that 
conciliates the two faces of this protein. EWS is recruited to potentially hazardous nucleic acid 
substrates, including G-quadruplexes and DNA breaks, but most remarkably to R-loops, tightly 
linked to RNA metabolism. This leads to a local concentration increase that favours 
polymerization into a hydrogel, which further recruits other LC-containing proteins to form a 
dynamic platform for orchestration of early events in response to R-loop accumulation (Figure 
39B). However, the precise molecular mechanism by which EWS resolves R-loops or prevents  
its formation remains elusive and requires further investigation. Impaired RNA export in EWS-
deficient cells suggests that the mechanism is related to nuclear export of transcripts. In this 
regard, EWS chromatin immunoprecipitation might clarify whether a direct interaction between 
EWS and R-loops or R-loop-prone genomic regions exist, and thus provide further insight into 
its molecular mechanism. 
In the light of this model, deleterious EWS mutations might facilitate aberrant aggregation at the 
cytoplasm into stress granules, composed of RNA and proteins (Bentmann et al., 2012; Bosco et 
al., 2010). The presence of diverse protein aggregates in degenerating neurons has been 
thoroughly described (Bosco et al., 2010; Kwiatkowski et al., 2009; Mackenzie and Neumann, 
2012; Takanashi and Yamaguchi, 2014), and the active – or passive – involvement of these 
aggregates in pathogenesis is a subject of debate. A hypothetical gain of function of aberrant 
FET protein aggregates might alter cytosolic RNA metabolism, which might have a cumulative 
effect eventually driving cellular degeneration and ALS pathogenesis (Baron et al., 2013). 
Conversely, following a loss-of-function model, FET protein cytosolic aggregates might 
essentially act to sequester additional LC-containing genome safeguarding proteins, thereby 
depleting the nucleus of functional units. Subsequent accumulation of R-loops and DNA 
damage would clog up the DNA-RNA-protein information flow of the cell, as supported by 
impaired RNA nuclear export in EWS-deficient cells (Figure 33). In the long term, this would 
contribute to a deficient cellular function and neurodegeneration (Figure 40). Genomic instability 
in FUS-KO and EWS-KO mouse models, and ALS-like phenotypes in adult EWS-KO mice 
support a loss-of-function mechanism rather than a gain-of-function of toxic, cytosolic protein 
aggregates, although these two possibilities are not mutually exclusive.  
In the context of translocations involving FET proteins, the LC domain of the FET protein is 
fused to the DNA binding domain of a transcription factor. The fusion protein lacks the C-
terminus of nucleic acid binding domains, which is replaced by the DNA-binding domain of a 
transcription factor (FLI1). This modification might lead to a number of consequences. First, 
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loss of the C-terminal region might prevent recruitment to C-terminal-dependent nucleic acid 
substrates such as R-loops. Second, and by the same reason, EWS interactors that depend on its 
C-terminus might be lost. Third, the fusion protein might be targeted to sites that differ from the 
original localization of EWS. Namely, the DNA binding domain contributed by FLI1 might 
localize the fusion protein to promoters specific to the transcription factor. Mislocalization and 
hydrogel polymerization in unscheduled sites might lead to sequestration of functional EWS and 
interactors, thereby depleting the cell of EWS and other genome safeguarding proteins. A similar 
effect was reported for RNAPII. It was shown that RNAPII interacted with LC-containing 
protein aggregates through its C-terminal domain (CTD). Based on this, it was proposed that  
 
Figure 40 
A model for pathogenesis derived from EWS deficiency.  Key mutations in EWS result in impaired recruitment to target sites and/or 
aberrant polymerization at unscheduled sites, thereby depleting the nucleus from EWS activity. This results into R-loop accumulation, 
which in the long term impacts on neuronal function and leads to neurodegeneration. EWS/FLI1 is targeted to FLI1 promoters or 
unscheduled genomic regions where it promotes hydrogel polymerization. EWS/FLI1 aberrant hydrogels sequester endogenous EWS 
molecules at unscheduled sites, thereby depleting the cell of EWS activity. R-loops accumulating in this context generate RS and genomic 
instability which might contribute to tumorigenesis.   
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localization and polymerization of EWS/FLI1 to FLI1 promoters leads to recruitment of 
RNAPII, which triggers unscheduled transcription favouring tumoral transformation (Kwon et 
al., 2013), which might explain the oncogenic mechanism of EWS/FLI1. Based on this 
polymerization-sequestration effect, we hypothesize that polymerization of the fusion protein in  
hydrogels at unscheduled sites might result in sequestration of functional EWS protein. This 
could explain the dominant-negative effect of EWS/FLI1 over EWS proposed throughout this 
work. In proliferating cells, depletion of functional EWS might lead to R-loop accumulation and 
increased RS levels, favouring tumoral transformation (Figure 40). Both mechanisms - gain of 
function of EWS/FLI1 and loss of function of EWS - are not mutually exclusive and might both 
contribute to tumorigenesis. 
6. A novel physiological role for R-loops? 
For the NOR-specific metaphase breakage analysis presented in this work we have used S9.6, an 
RNA:DNA hybrid-specific antibody as a tool to label NOR regions and analyse NOR breakage. 
Nonetheless, the presence of R-loops in metaphases (Figure 30) is per se a novelty: R-loops have 
not been described to persist throughout mitosis before. The presence of RNAPI and UBF in 
NORs on metaphase chromosomes was reported in some early works (Roussel et al., 1996; 
Weisenberger and Scheer, 1995). In those works they proposed that the persistence of 
transcriptional machinery attached to metaphasic NORs served to restart rRNA transcription 
immediately after chromosomal segregation, at telophase. Our observation that RNA:DNA 
hybrids persist on NORs supports this hypothesis and suggests that rRNA transcription is 
frozen at the elongation or termination level, and transcripts retained at their loci. Consistent 
with this, R-loops are thought to slow down or block transcription at the elongation/termination  
(Aguilera and Garcia-Muse, 2012). We can speculate on alternative functions for metaphasic 
NOR-associated R-loops. A very detailed work by Heliot and colleagues on the 3D organization 
of metaphasic NORs described these structures as 60-80 nM fibers emanating from the 
chromosomal axis and coiled around it (Heliot et al., 1997). The presence of DNA within these 
fibers was validated, and we now know that they also contain an RNA fraction that forms 
RNA:DNA hybrids. Interestingly, on our S9.6-stained metaphase spreads we sometimes 
observed some of the NOR-bearing chromosomes lying together and precisely aligned along 
their NORs (data not shown). This, together with the idea of chromatin fibers emanating from 
the chromosome and coiled around to form the structure of the NOR, suggests a possible 
structural role of NORs during metaphase. Intertwined NOR fibers might facilitate 
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interchromosomal organization during mitosis. Furthermore, and on a purely speculative basis, 
the intertwined RNA component at metaphasic NORs might serve as a security lock preventing 
premature segregation, or instead as a segregation sensor. Further work is needed in regards to 
determine a role for R-loops during mitosis. 
 
To sum up, we have identified R-loops as the molecular basis of the vulnerability of Ewing 
sarcoma to TopoI inhibitors and to RS-inducing agents, and we provide a rationale for the use of 
ATR inhibitors for the treatment of Ewing sarcomas. We have determined a role for EWS 
protein in suppressing R-loop accumulation, which contributes to the maintenance of genome 
integrity. In Ewing sarcomas, loss of EWS activity might be responsible for R-loop 
accumulation, although the hypothesis of a dominant-negative effect of EWS/FLI1 over EWS 
remains to be strengthened. Whereas R-loop accumulation in Ewing sarcomas constitutes a 
vulnerability that can be exploited for treatment, the possible contribution of R-loop-derived 
genomic instability to tumorigenesis is still unanswered. An unexpected ALS-like phenotype in 
mice with EWS deletion in the adult stem cell compartment has highlighted the role of EWS in 
R-loop metabolism and has provided further insight in the ethiology of neurodegenerative 
diseases such as ALS or FTD. Whereas a gain-of-function model of mutant proteins has been 
widely attributed to the ethiology of these pathologies, our knockout mouse model rather 
supports a loss of function of R-loop-processing factors as the cause of disease. Finally, the 
detection of R-loops on metaphasic chromosomes opens a new field of study for R-loop 
biology. 
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CONCLUSIONS 
 
 
PART I 
 
1. FBH1 contributes to the signaling of RS, but has no impact on RS-driven toxicity. 
 
2. FBH1 does not regulate Rad51 in vivo nor it rescues the viability of HR-deficient cells. 
 
3. FBH1 is largely dispensable for mouse health. 
 
 
PART II 
 
4. Ewing sarcomas suffer from increased RS and are hypersensitive to ATR inhibition. 
 
5. EWS protein limits RS and genomic instability, and its deletion sensitizes to ATR 
inhibition in vivo. 
 
6. EWS protein prevents R-loop accumulation. 
 
7. EWS favours nuclear export of RNA molecules. 
 
8. Constitutive EWS deletion in mice leads to anemia and embryonic lethality. 
 
9. EWS deletion in adult stem cells does not promote tumorigenesis in mice.  
 
10. EWS deletion in adult stem cells leads to an ALS-like phenotype in mice. 
 
 
  
  CONCLUSIONES 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
109 
CONCLUSIONES 
 
 
PARTE I 
 
1. FBH1 contribuye a la señalización del RS pero no tiene un impacto en la toxicidad 
derivada del RS. 
 
2. FBH1 no regula a Rad51 in vivo ni rescata la viabilidad de células deficientes en HR. 
 
3. FBH1 es prescindible para la salud de los ratones. 
 
 
PARTE II 
 
4. Los sarcomas de Ewing presentan altos niveles de RS y son hipersensitivos a la 
inhibición de ATR. 
 
5. La protein EWS limita el RS y la inestabilidad genómica, y su deleción sensibiliza a la 
inhibición de ATR in vivo. 
 
6. La proteína EWS previene la acumulación de bucles-R. 
 
7. La proteína EWS promueve la exportación nuclear de moléculas de RNA. 
 
8. La deleción constitutive de EWS en ratones produce anemia y letalidad embrionaria. 
 
9. La deleción de EWS en células madre adultas no promueve tumorigénesis en ratones. 
 
10. La deleción de EWS en células madre adultas da lugar a un fenotipo similar a esclerosis 
lateral amiotrófica en ratones.  
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